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ABSTRACT OF DISSERTATION

SUCCINYLATED POLYETHYLENIMINE GENE DELIVERY AGENTS FOR
ENHANCED TRANSFECTION EFFICACY
Gene therapy aims to treat patients by altering or controlling gene expression. Today,
most clinical approaches are viral-based due to their inherent gene delivery activity.
However, there is still a significant interest in nonviral alternatives for gene delivery,
particularly synthetic lipids and polymers, that do not suffer the immunogenicity, high
cost, or mutagenesis concerns of viral vectors. Polymeric vectors are of particular interest
due to the ability to further tune the polymer properties through the incorporation of
additional functional units such as targeting ligands or shielding domains.
Polyethylenimine (PEI), a highly cationic polymer, is often considered a benchmark for
polymer-based gene delivery and thus serves as an excellent model for investigating gene
delivery mechanisms. One reason PEI, especially branched PEI, is thought to outperform
many other cationic polymers is due to the presence of secondary and tertiary amines.
These amines are thought to help facilitate escape from endocytic vesicles via a 'protonsponge' mechanism. Despite its successful use for in vitro gene delivery, PEI was initially
developed for use in common processes such as water purification. As such, the
properties of PEI should not be expected to be optimal for gene delivery. In this
dissertation, my research efforts focused on the incorporation of negatively charged
succinyl groups to the PEI backbone to create succinylated zwitterion-like PEI (zPEIs).
Specifically, we focused on the synthesis and characterization of zPEIs as well as the
impact of zPEI on DNA condensation and gene expression.
This dissertation will discuss the results of three projects. In project (1), we studied
the suitability of minimally modified zPEIs for gene expression. In this work, we reveal
that modification of PEI as low as 2% amines was sufficient to provide significant
improvements in gene delivery particularly in the presence of serum proteins. In project
(2), we investigate the self-assembly of DNA induced by modified and unmodified
branched PEIs using small-angle X-ray scattering (SAXS). Modified PEIs included both
succinylated zPEI and acetylated PEIs (acPEI) both modified from 0-40%. We
demonstrate that changing the degree of modification significantly alters the packing
density of the resulting polyplexes. While acPEI shows a continuous decrease in DNA

packaging efficiency with increasing degree of modification, zPEI shows a crossover
behavior where DNA-DNA interhelical spacings increase at low succinylation but
decrease at higher degrees of succinylation. Studies on the pH dependence on the interDNA spacing also show that lowering the pH leads to tighter DNA packaging for all PEIs
studied. These findings shed light on the complex correlation between DNA packaging
density and gene expression ability of PEI and modified PEI mediated gene delivery
systems. In project (3), we studied the efficacy of zPEI polyplexes at varying protein
concentrations ranging from 0-10 mg/mL of bovine serum albumin (BSA). These high
protein concentrations are comparable to in vivo protein concentrations. We show that
while PEI/DNA transgene expression decreases with higher protein concentrations, the
zPEI studied stayed approximately constant over the protein range studied. To test if
these conditions may lead to the formation of a protein corona on the nanoparticles,
which was recently shown to enhance serum-free transfection in unmodified bPEI/DNA,
we also measured the transgene expression of polyplexes pre-treated to form a protein
corona on the polyplexes.
KEYWORDS:
Succinylated PEI, Gene delivery, Small-angle X-ray scattering,
Packaging density of dsDNA in polyplex, Proton sponge effect, Protein corona
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CHAPTER 1. RECENT ADVANCES AND CHALLENGES WITH NONVIRAL GENE
DELIVERY SYSTEMS
1.1

INTRODUCTION
Gene therapy is emerging as a promising treatment option for certain genetic

diseases with the potential to transform therapeutic treatments for patients living with
currently untreatable diseases. In its simplest form, gene therapy aims to regulate, repair,
or replace genetic materials employing recombinant nucleic acid. In recent years, this
genetic approach has treated diseases such as spinal muscular atrophy, Duchenne's
muscular dystrophy, Beta-thalassemia, and cystic fibrosis and the list continues to grow.
In addition, researchers are slowly uncovering the genetic basis of acquired
neurodegenerative diseases such as Alzheimer's, cancer, type 2 diabetes, etc. providing
new targets for future gene therapies. To date, there are 22 FDA-approved cellular and
gene therapy products and over 500 ongoing studies on gene delivery listed on
clinicaltrials.gov. Although most clinical trials worldwide address gene transfection using
a virus as a vector, the history of virus-mediated gene therapy has not been smooth. Most
current viral vector-based gene delivery uses retroviruses, lentiviruses, adenoviruses or
adeno-associated viruses to transport a therapeutic gene for in vivo delivery. Viral vectors
have the inherent advantage of higher delivery efficiency and an ability to target cells.
However, viruses trigger immunogenic responses and mutagenicity, which could be fatal
to a patient. The treatment induced cancer in some volunteers, and the tragic death of 18year old Jesse Gelsinger, overshadowed initial success in gene therapy in the late 1990s,
sparking a chain of events that nearly derailed the field.1 This fear of massive immune
response to viral vectors urged researchers to seek new alternative strategies to viral gene
delivery, thus developing various nonviral, synthetic vectors.
1

1.2

Literature review on gene delivery agents
Genes are sequences of nucleotides embedded into deoxyribonucleic acid (DNA)

that provide the blueprints for protein synthesis critical for the proper functioning of cells
and organisms. Small changes to genes, either through random process mutation or
inherited, can alter the expression of proteins, impacting the body’s ability to function
properly. In gene therapy, the goal is to deliver genetic materials, in the form of DNA or
ribonucleic acid (RNA), that have the instructions to repair protein synthesis, thus
producing a therapeutic response. To be successful, however, these nucleic acids need to
be targeted for delivery to the cells or tissues identified to contain faulty genes. Naked
nucleic acids alone cannot serve this purpose due to many complex biological systems
posing barriers as depicted in Figure 1.1. First, these materials should avoid the
reticuloendothelial systems (RES) and macrophage systems, which poses the first barrier
after intravenous injection. Serum nuclease is another major hurdle for gene delivery.
Next, therapeutic nucleic acids must overcome the challenge of endocytosis at the cell
membrane level, which is a requirement for cell entry. Depending on the type of therapy,
the payload must reach specific points in the cell. For example, upon entering a cell,
noncoding RNA (such as micro-RNA and siRNA) must be delivered in the cytosol while
DNA needs to reach the cell nucleus for transcription to occur. These multiple barriers
are why a protecting vector is required to package the genetic payload and traffic them to
the desired target site. Currently, vectors for gene therapy are broadly classified as viral,
nonviral, and hybrid vectors. The following section will explore the advancement and
challenges associated with these vectors.
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Figure 1.1. Barriers to viral and non-viral vectors. For simplicity, only nonviral model
(polyplex) was used to describe all the challenges associated with gene delivery. A
successful gene delivery agent must evade all these barriers to successfully express the
transgene.
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1.2.1

Viral vectors

Viruses have been evolved by nature to overcome most of the biological barriers
depicted in Figure 1.1. The primary advantages of viral gene delivery lie with the innate
ability of viruses to deliver genes in a highly specific manner to targeted cells as well as
their capacity for efficient gene transduction. Due to these advantages, viral vectors
currently have taken the leading role in gene therapy research. More than 70% of clinical
gene therapy trials worldwide utilize viruses, primarily adenovirus, adeno associated
virus (AAV), retroviruses, and lentiviruses.2-4
Adenoviruses are a non-integrating virus that transiently expresses their genes in the
cytoplasm of cells. Adenovirus vectors have three main advantages: (1) they can
transduce a variety of dividing and non-dividing cells (2) they can achieve a high level of
gene expression and (3) certain common strains are easily purified and wellcharacterized.5 Due to its nonpathogenic nature and broad tropism, adeno-associated
virus (AAV) have also shown strong potential for in vivo gene therapy.6 AAV is a nonenveloped virus that can be engineered to deliver nucleic acids (NAs) to target cells. The
ability to generate recombinant AAV particles lacking any viral genes with DNA
sequences of interest for therapeutic applications has proven to be one of the safest
strategies for gene therapies.7 However, AAVs are small in size (20-24 nm) limiting the
size of genes it can deliver, so strategies involving the use of split AAV vectors and the
reassembly of AAV genome fragments have been used to address AAV packaging
capacity.8 These modified AAV vectors have enhanced the success of AAV therapies
which continue to grow at a fast pace in recent years. Retroviruses are enveloped RNA
viruses that carry virally encoded elements that reverse transcribe their RNA payload into
4

double-stranded DNA (dsDNA). This dsDNA is then transported to the cell nucleus and
stably integrated into the host genome employing a virally encoded integrase.4, 9 While
designing a recombinant virus, the retroviral genes (gag, pol, and env) are deleted and
replaced with the therapeutic gene(s) of interest.4 Murine leukemia virus are among the
simplest retroviruses and named after their ability to cause cancer in mice. Moloney
murine leukemia virus (MMLV) have been optimized for stable chromosomal integration
and gene expression. With a transduction efficiency of more than 90% in dividing cells,
MMLVs are one of the most studied retroviral vectors.10 Lentiviral vectors (LV) have
been extensively investigated and optimized over the past two decades.11 First-generation
LVs used significant portions of the HIV genome but in later generations various changes
were made to create safer vectors. For example, self-inactivating LVs are used to
introduce genes into hematopoietic stem cells to correct primary immunodeficiencies and
hemoglobinopathies.12 More recently, non-human lentiviruses have become attractive
alternatives to conventional HIV-1-based LVs.13 In 2017, the FDA approved its first gene
therapy drug, named Kymriah, that uses lentiviruses as the transfecting agent.14 With
increasing interest in gene therapy, ongoing research is also recruiting other viral vectors
such as vaccinia virus, herpes simplex virus, and poxvirus, comprising 4.9%, 3.6%, and
2.7% of all clinical trials, respectively.5, 15

1.2.1.1 Recent advances and challenges with viral vectors
Although gene therapy trials are on the rise, understanding the long-term risks
associated with this type of treatment is necessary. According to an editorial published
in 'Nature Medicine,' Bluebird Bio suspended phase 1/2 and phase 3 clinical trials of its
5

LentiGlobin gene therapy for sickle-cell disease very recently after two patients were
diagnosed with cancer, five years after receiving treatment.16 Earlier, in late 2018,
another participant from the same trial had been diagnosed with myelodysplastic
syndrome.16 Although further review indicates that the lentiviral vector used in the
studies is unlikely to cause cancer, this news highlights growing concerns about the late
adverse effects of gene therapy.16 In January 2020, the FDA updated guidelines on
designing long-term follow-up studies using integrating vectors, genome-editing
products, and AAV, hoping to better evaluate the long-term effects of gene therapy
products on patients.
The major challenge with viral vectors is safety. As recently as this past year,
deaths occurred in children with X-linked myotubular myopathy (MTM) being treated by
AAV gene therapy serving as a reminder how difficult it is to predict outcomes in firstin-human studies.
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Some hypotheses to explain this event have focused on the role of

antibodies to AAV that either preexist or rapidly accumulate following vector infusion.17
One major issue during the manufacturing and production of AAV vectors is the presence
of empty capsids lacking the encapsidated vector genome. These empty capsids can elicit
additional immune responses during in vivo gene therapies if not removed prior to
treatment.18 Another significant issue is the viral vector heterogeneity during lot-to-lot
production. One approach to prevent the viral serotype variability is the post-translational
modification of the capsid. For example, capsid deamidation to impact the transduction
efficiency is a promising strategy to improve performance.19 However, there needs to be
a balance between vector performance and stabilized variants in a more complex
functional context to succeed with such an approach. The application of machine learning
6

algorithms to accurately predict capsid viability across diverse variants might unlock vast
areas of functional sequence space, with potential applications for the generation of
improved, safer viral vectors.20

1.2.2

Nonviral delivery systems
While viral gene delivery is currently dominating current clinical trials, viruses

have many drawbacks including concerns regarding their safety (such as immunogenicity
and oncogenicity), limited genetic payloads, and difficulties in scaling up production of
viruses to meet commercial demands. Therefore, much work has been done to find
alternatives to virus for gene delivery. Synthetic, or nonviral formulations typically
utilize cationic polymers or lipids as the delivery vehicle for nucleic acids. Unlike the
logistic challenges with viral vectors, synthetic vectors are easy to scale up, readily
formulated, and made available off the shelf, have the capacity to deliver larger payloads,
and have reduced immunogenicity.21 The possibilities for these nonviral vectors has
recently been shown by the success of lipid formulations, originally developed for
nonviral gene delivery, in the formulation of mRNA-based vaccines for COVID-19.22-23
The delivery of mRNA suffers from all the challenges of delivery any nucleic acid for
gene therapy. Lipid nanoparticles are used to protect mRNA during the production and
transport of the vaccine as well as enhance their stability in vivo once the vaccine is
administered. One clear drawback of the lipid formulations was the requirement that they
must be refrigerated during transport and storage. Worldwide distribution of these lipidnucleic acid complexes, and affordability in developing countries with infrastructural
deficiencies in the cold chain therefore pose a significant challenge.24 Due to these
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challenges, both clinicians and biotechnologists widely acknowledge the need for
synthetic delivery methods which will be safe and affordable by the mass community.25-26
The success of the two lipid-based mRNA vaccines for COVID-19, distributed to
hundreds of millions of people in the US alone, has triggered a renewed research interest
in non-viral gene delivery platforms.
Cationic lipids, cationic peptides, chemically stabilized DNA/RNA, and cationic
polymers have all been used as nonviral gene delivery agents in various laboratory
studies and pre-clinical trials. Each synthetic gene delivery modalities have their own
advantages and limitations. For example, cationic lipids, usually in the form of
liposomes, are capable of condensing nucleic acids but their effectiveness depends on
their hydrophobic tails. Cationic polymers are known to have stronger DNA binding
ability compared to the liposomes and have been shown to result in higher transfection
efficiency in vitro.27 Polymers are also more amenable to the incorporation of additional
functional units, such as targeting ligands or shielding domains to facilitate
multifunctional delivery systems. Through electrostatic interactions, cationic polymers
condense DNA into nanometer-sized complexes called polyplexes. Upon condensation,
polyplexes protect nucleic acids from enzymatic degradation and facilitate cargo delivery
to cells. Upon reaching the cells, polyplexes can bind cell membranes that can trigger
intracellular uptake of the particles. Ultimately the polycation must release the nucleic
acids for successful gene delivery creating a need to optimize the polymer-NA
interactions to optimally balance the protection and release of the payload. Some
examples of commonly used polymers are shown in Figure 1.2. The following sections
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will briefly highlight critical advances in designing synthetic polymeric vectors and the
different materials that comprise these carriers.

Figure 1.2. Examples of common polymers used in gene delivery.

1.2.2.1 Cationic polymer design with tunable motifs
Typically, cationic polymers consist of nitrogen-based moieties that can be
integrated via direct polymerization or post-polymerization modification to noncationic
polymers. Polycations with ammonium, imidazolium, and guanidinium moieties are
commonly found in the literature as potential polyplex vectors. Along with balancing
condensation and release, another significant barrier for nonviral delivery is the escape of
the polyplexes from the endosome. While viruses have fusion peptides that allow them to
9

escape endosomes from membrane fusion and lipoplexes can enter cells through fusion
with the cell membrane, polycations are not fusogenic. It is thought that one possible way
to aid endosomal escape is by using cationic polymers with a pKa near physiological pH
to act as a "proton-sponge". For example, the imidazolium group can obtain a pKa close
to 7 thus resulting in a low charge at neutral pH that becomes charged during
acidification thus thought to change the internalization pathway and improve gene
transfection.28 Another reason for a low pKa polycation is that higher pKa polymers are
known to cause cytotoxicity. To date, a limited number of non-nitrogenous polycations
containing phosphorous and sulfur atoms have also been reported in the literature.
However, the scarce use of these atoms in gene delivery is predominantly due to fewer
synthetic pathways and the concern of chemical instability in biological environments.29
Introducing hydrophobic moieties is another strategy utilized to fine-tune
polymeric vectors to improve gene delivery efficacy. Incorporating hydrophobic groups
into a polymeric vector induce hydrophobic−hydrophobic interactions with nucleic acids.
These additional hydrophobic interactions have been shown to improve complex
stability, enhance cellular uptake, and prolongs circulation time in vivo by slowing sown
renal clearance.30-31 Hydrophobic moieties, such as linear alkyl, cyclic alkyl, lipidic, aryl,
and cholesteryl groups have been incorporated into cationic polymers to enhance gene
transfection.32 Low molecular weight polyethylenimines (LMW-PEI) are one of the
prime candidates for introducing hydrophobicity to improve their gene delivery
efficiency.33-34 LMW-PEI (typically ~5-12 kDa PEI) shows higher cell viability but lower
transfection efficacy when compared to higher molecular weight PEIs such as 25kDa
PEI. Incorporating hydrophobic moieties on LMW-PEI has been shown to enhance gene
10

delivery.35-36 The introduction of hydrophobic moieties has also been explored in other
polycationic systems. In 2010, Piest et al. showed that incorporating hydrophobicity into
a bio-reducible poly(amido amine) resulted in enhanced transfection efficiencies through
reduced cytotoxic effects, increase polyplex stability, and improved endosomolytic
properties.37 Polycationic micelles formed from triblock copolymers containing a nonionic hydrophilic block in addition to a cationic and a hydrophobic block have also been
used as components for micelleplex formulations.21 The use of these micelleplexes has
been reported to co-deliver plasmid DNA and small molecule drugs for cancer therapy by
taking advantage of the hydrophobic interactions between the drug and the hydrophobic
block of the polymer micelle.38
Because polyplexes encounter different physiological conditions, such as varying
pH, while trafficking the nucleic acid payloads into cell nuclei the incorporation of
stimuli responsive moieties has also been a common strategy for enhanced gene delivery.
For example, the use of an acid cleavable block copolymer of polyethylene glycol (PEG)
and a modified poly(aminoethyl methacrylate) (PAEMA) was recently shown to deliver
pDNA into tumor cells effectively.39 The cleaving of PEG was shown to result in a
change in the polyplex surface charge upon acidification that enables the complexes to
better circumvent high blood clearance and minimize cytotoxicity.39 Addition of photo
responsive and redox-responsive moieties to a polymer are other strategies commonly
employed to enhance gene delivery. In more recent years, research has focused on using
multi-stimuli-responsive polymers to co-deliver drugs and nucleic acids to hard-totransfect cells or drug-resistant cancers.
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Most polyplexes result in the formation of DNA nanoparticles with a positive
surface charge which can lead to stability issues in vivo such as polyplex aggregation
with proteins and tissue damage. Serum-protein binding and colloidal instability often
lead these polymer vehicles to be cleared out of in vivo circulation via reticuloendothelial
systems. Polyethylene glycol (PEG) is a hydrophilic, uncharged flexible polymer.
Incorporating PEG into polyplex formulations is a common means to shield the polyplex
surface charge and reduce nonspecific interactions of the polyplex with surrounding
molecules.40 Although PEG has been shown to aid in tackling in vivo challenges, it
markedly reduces cellular internalization, thus hampering gene expression. To improve
transfection with PEGylated polyplexes, more recent studies have focused on optimizing
PEG grafting density and PEG molecular weights for different polyplexes.41-42 Recent
studies have also examined the immunogenic and allergic response associated with
PEGylated polymer mediated gene delivery.43 Recently, it was shown that some people
produce anti-PEG antibodies that may limit the activity of PEGylated particles.44-45
Researchers are therefore also exploiting alternatives to PEG such as incorporating
carbohydrate or zwitterionic moieties as hydrophilic agents that mitigate nonspecific
interactions of molecules with the polyplexes.46-47.

1.2.3

Polyethylenimine (PEI) at the forefront of gene delivery research
Polyethylenimine (PEI) is one of the most studied polycationic polymers in

nonviral gene delivery and often considered a benchmark for polyplex gene delivery
vectors. PEIs have a high cationic charge density and significant buffering capacity over
a wide range of pHs. Branched PEI (bPEI), containing a mixture of primary, secondary,
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and tertiary amino groups with different pKa values, results in the protonation state of
PEI being pH dependent. At neutral pH, it is estimated bPEI has ~20-25% of its amines
protonated but this can increase to ~45% protonated at pH 5.48 From the PubMed
database, more than two thousand articles using PEI for gene delivery have been
published since 2000, revealing their significance in the field. However, due to the very
high positive charge density of the polymer, PEI generally is cytotoxic, often posing a
threat to cell viability. To circumvent this cytotoxicity, more recent research has focused
on decreasing PEI charge density via post polymerization modification to enhance cell
survival.
The recent development on the design and synthesis of PEI-based nanocarriers
broadly focuses on i) PEI-based polymeric nanoparticle system; ii) PEI-based polymeric
micelles systems; iii) PEI/silica nanoparticle systems, and iv) PEI/metal nanoparticle
systems.49 Commonly used functionalities for these modifications include but are not
limited to polyethylene glycol (PEG), polysaccharides, poly (ε-caprolactone), small
molecules & peptides, proteins, and poly (l-lactide) (PLLA).50 PEI-based co-delivery
strategies are also being explored as a new method for treating diseases by combining
chemotherapy and gene therapy.51 Some examples of co-delivery strategies include
blocking NF-kB activation in inflammatory tissue,51 improving antitumor efficacy and
systemic toxicity,52 and reversing multidrug resistance (MDR) in cancer to more
effectively kill MDR cancer cells.53

13

1.3

CONCLUDING REMARKS
The list of nonviral-based gene therapy vectors is continuously expanding due to

continuing interest in gene therapy. Surprisingly, the progress in nonviral agents with
polymeric scaffolds has not yet achieved clinical relevance. Many barriers to nonviral
gene delivery have not been fully understood yet. Therefore, we must understand how
polymer synthesis and modification affect the body's gene delivery mechanism and
vector interactions.
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CHAPTER 2. ENHANCED GENE DELIVERY AND CRISPR/CAS9 HOMOLOGYDIRECTED REPAIR IN SERUM BY MINIMALLY SUCCINYLATED
POLYETHYLENE IMINE
This chapter is reprinted with permission from [Uddin, N., Warriner, L. W., Pack, D. W.,
and DeRouchey, J. E. (2021) Enhanced Gene Delivery and CRISPR/Cas9 HomologyDirected Repair in Serum by Minimally Succinylated Polyethylenimine. Molecular
Pharmaceutics, 18 (9), 3452-3463. https://doi.org/10.1021/ acs.molpharmaceut.1c00368]
Copyright © 2021 American Chemical Society.
All polymer synthesis and characterization, DNA binding assays, dextran sulfate
displacement, DLS and ζ-potential measurements were completed by the author. Protein
interaction, transfection, and CRISPR/Cas9 experiments were done by the co-first author
Dr. Logan Warriner and performed in the laboratory of Dr. Daniel Pack.

2.1

INTRODUCTION
Therapeutic nucleic acids (NAs) are proving to be powerful tools capable of

altering or controlling gene expression with the potential to treat intractable acquired and
inherited diseases including cancer, neurodegenerative diseases, and genetic defects.54 To
date, more than a dozen different gene therapy drugs for treating immune and neuronal
disorders, blindness, and cancer, as well as vaccines protecting against SARS-CoV-2,
have been approved world-wide.55 Promising clinical trials for sickle cell, hemophilia,
neuromuscular diseases, and vaccines will also likely lead to additional approvals in the
near future. The efficacy and clinical success of these therapies have been hindered to
date primarily by the requirement for effective delivery of nucleic acids into specific
intracellular locations and organelles within targeted tissues.56-57 Recombinant virusbased delivery vehicles have accounted for the vast majority (~70%) of clinical trials due
to their inherent gene delivery activity.58 However, viruses have drawbacks including
difficulty in producing commercially relevant quantities59-60, high costs, limited genetic

15

payloads61, and potential for insertional mutagenesis62, immunogenicity63 and
oncogenecity.64
Nonviral or synthetic gene vectors have several advantages that give them the
potential to overcome the inherent limitations of viral vectors.65-67 Nonviral vectors
typically condense negatively charged nucleic acids (NA) with cationic polymers or
lipids to form nanoscale complexes known, respectively, as polyplexes or lipoplexes.
Synthetic vectors allow for lower cost, ease of large-scale production, and improved
safety potential while also the capacity to accommodate various kinds of NA payloads.
For example, non-viral vectors may deliver plasmid DNA or mRNA to introduce a
therapeutic gene product; siRNA or miRNA for silencing or regulation of specific genes;
or CRISPR/Cas9 components for editing the target cell genome to permanently knock-in
a therapeutic gene, knock-out an undesirable gene, or introduce specific point mutations
to correct an aberrant gene. In addition, nonviral vectors hold advantages over
recombinant viruses when short-term expression of the transgene is desired, as in the
expression of Cas9 in CRISPR-based therapies.68 The use of polymer vectors also
facilitates multifunctional delivery systems through the incorporation of additional
functional units such as targeting ligands, shielding domains, and endosomolytic units to
improve efficacy.69-70 To date, however, synthetic polyplexes suffer from lower delivery
efficiency relative to viral vectors due to complications including the creation of poorly
defined formulations, the need to balance NA protection and release, lack of serum
stability, rapid clearance, and inefficient targeting.71-72 There is still a need for a better
fundamental understanding of the complex correlations of physicochemistry and biology
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of synthetic delivery systems to improve efficacy in vivo and move nonviral gene therapy
into clinical use.
The size, stability, shape, and surface properties of these polyplex nanoparticles
are known to play a critical role in cellular uptake processes and in-vivo
biodistribution.73-74 Therefore, the chemical structure of the polymer used for polyplex
formulations is known to be a key determinant for polyplex efficacy and toxicity.
Polyethylenimine (PEI) is often considered a benchmark for polymeric, nonviral gene
delivery vectors thus serving as an excellent model for investigating gene delivery
mechanisms.75-77 PEI is a highly cationic polymer that readily condenses NAs through
electrostatic interactions to create suitable particles for effective gene delivery. Complete
complexation of NAs with PEI results in polyplexes with a net positive surface charge,
which has been shown to promote interactions with the negatively charged components
of the cell membrane.78 In addition, the substantial quantity of secondary and tertiary
amines in branched PEI results in a large buffering capacity, thought to facilitate escape
from endocytic vesicles, a crucial bottleneck in the transfection process, via the ‘protonsponge’ mechanism.79 However, PEI was originally developed nearly 50 years ago as a
chelator for use in the water purification and mining industries.80 As such, the properties
of PEI should not be expected to be optimal for gene delivery.81 The excess positive
charge typical of PEI/DNA polyplexes induces nonspecific binding to negatively charged
serum proteins, which leads to polyplex aggregation and, ultimately, clearance by the
reticuloendothelial system.82-83 The high charge density can also contribute to
cytotoxicity, causing changes in cellular morphology, damage to the cell membrane,
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decreased metabolism, and lysis.84 Finally, the strong electrostatic interactions between
PEI and DNA can hinder vector unpackaging, which is required for transcription.85-86
Due to high cytotoxicity, endosomal degradation, and aggregation on cell surfaces
encountered with native PEIs, chemical modification of PEI has been a common strategy
to enhance performance.75,

87

Many of these modifications have focused on means to

reduce a net cationic charge of the resulting polyplexes. For example, acetylation of
primary and secondary amines on PEI (acPEI) resulted in polymers exhibiting enhanced
gene delivery, demonstrating the relative importance of buffering capacity and
polymer/DNA binding strength in PEI-mediated gene delivery.88-89 Acetylation was
shown to weaken polymer/DNA interactions and dissociate more readily within cells
leading to enhanced transgene expression in vitro. Transfections of acetylated PEI in the
presence of serum however resulted in lower activity suggesting acPEI still suffered from
serum instability due to aggregation. To decrease aggregation in serum and increase
retention in the bloodstream, incorporation of shielding domains, such as polyethylene
glycol (PEG), has been a commonly employed strategy.82, 90 PEGylation has been found
to possibly induce immune responses,91 leading to studies of alternative shielding
domains for PEI including polyethers,92 poly(N-(2-hydroxypropyl)methacrylamide),93
and dextran94. Polyplex shielding has been shown to improve blood circulation times and
increase accumulation within tumors compared to unmodified PEI. Polyplexes
comprising such modified PEI, however, suffer from a reduced cellular uptake and
decreased transfection efficiency.
Less commonly studied has been the incorporation of negatively charged groups
to polycations to generate polyampholytic vectors suitable for polyplex formation. Early
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work focused on charge-shifting polymers which under physiological acidification
converted neutral esters to anionic carboxylates.95-96 These materials were shown to
modify polymer-DNA interactions and enhance gene delivery of linear PEI.

More

recently, work on succinylated PEIs showed a significant increase in effectiveness for the
delivery of siRNA compared to unmodified PEI,97 typically a poor siRNA carrier, with
the targeted gene expression reduced to nearly 10% of the relative control. In 2017,
Khalvati et al. showed modest improvement of DNA delivery under serum-free
conditions by succinylated PEIs modified at 10−40% of their amines.98 We recently
synthesized a series of succinylated PEIs with modification of 9-55% of amines on the
polymer to create zwitterion-like PEI (zPEIs) and examined the gene delivery efficiency
in vitro in the absence and presence of serum.99 Lower modifications (9-25%) were found
to be most effective for gene delivery. While these succinylated PEIs also showed only
modestly improved transfection efficiencies (~5 to 10-fold) in the absence of serum, the
most surprising aspect of the zPEIs was the highly effective in-serum transfection. For
unmodified PEI, the presence of serum during transfection is well known to result in a
significant decrease in the transfection efficiency. For example, we previously observed a
decrease in gene expression of 10- to 20-fold for HeLa and MDA cells and over 100-fold
in MC3T3 cells for PEI/DNA transfected in-serum when compared to serum-free
conditions.99 In contrast, a 9% modified zPEI mediated transgene expression in the
presence of serum that was comparable to, or even surpassed (up to 51-fold), that of
unmodified PEI/DNA in the absence of serum in all three cell lines. We further showed
that high degrees of succinylation decreased polymer/DNA interactions while reducing
aggregation in the presence of anionic proteins and lowering cytotoxicity.
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In this work, we focused on examining two critical questions: (i) what the minimum
amount and optimal range of succinylation is required to observe improvement in gene
expression in the presence of serum, and (ii) does zPEI also enhance CRISPR/Cas9 gene
knock-in modifications in the presence of serum. To address these questions, a series of
minimally modified zPEIs (2-11.5%) were synthesized and characterized by FT-IR and
1

H-NMR. These sparsely modified zPEIs remarkably all show similarly enhanced

transfection efficacy in the presence of serum, as previously observed.99 Most
surprisingly, modification levels as low as 2%, corresponding to ~12 of 581 amines in
25kDa PEI, were sufficient to enhance transfection, including remarkably increased
efficiency of CRISPR/Cas9-mediated knock-in, in the presence of serum. We previously
hypothesized that a hydration barrier around the mixed-charge zPEI/DNA polyplex may
account for the increased protection from serum-protein binding and aggregation. The
minimally functionalized zPEIs were, therefore, directly compared to a commercial PEIPEG2k to assess relative biocompatibility and cytotoxicity. We show that while
PEGylation more effectively shields the resulting polyplexes against protein aggregation,
the minimally modified zPEIs still significantly outperform the PEGylated particles in the
presence of serum in both HEK293 and HeLa cells.

2.2

2.2.1

MATERIALS AND METHODS

Materials
25-kDa branched polyethylenimine (bPEI), succinic anhydride, and dextran

sulfate (9-20 kDa from Luconostoc spp) were purchased from Sigma Aldrich (St. Louis,
MO). D2O was purchased from Cambridge Isotope Laboratories (Andover, MA).
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Plasmid DNA pUC19 (1 mg/mL) was purchased from New England Biolabs (Ipswich,
MA). Solid agarose I and 0.2 µm syringe filter units were purchased from VWR Life
Science (Randor, PA). Bromophenol blue was purchased from Eastman Kodak
(Rochester, NY). PEGylated, branched polyethylenimine (10% amines modified with 2
kDa PEG) was purchased from Nanosoft Polymers (Winston-Salem, NC). All other
materials and chemicals were purchased from Thermo Fisher Scientific (Waltham, MA)
and used without further purification.

2.2.2

Synthesis and characterization of zPEI
Succinylated, or zwitterion-like PEI (zPEI) was synthesized as follows. 0.5 gram

of branched polyethylenimine (bPEI, 25kDa) was dissolved in 3 mL of sodium
bicarbonate buffer (HCO3, pH 9) and reacted with the desired mole ratio of succinic
anhydride. The succinylation reaction proceeded for 4 hours at 60 ºC and the final
product, zPEI, was purified by dialysis (membrane molecular weight cutoff = 3.5 kDa)
against double distilled water for 24 hours with the water replaced every 4 hours. After
dialysis, the solution was filtered through a molecular-weight cutoff filter (EZFlow
Syringe Filter with Foxx Hydrophilic PVDF membrane, 0.22 µm). Upon re-dissolving,
the zPEI solutions were often observed to have some cloudiness which was not removed
with filtering. To improve the solubility of the zPEIs, all polymers were subsequently
buffered to pH 7 by addition of HCl (0.1M) clarifying the solutions. After acidification,
the product was frozen overnight and lyophilized for 24 hours. The dried product was
placed in a -80 ºC freezer for storage. Successful reaction and percent succinylation were
determined by FT-IR and 1H NMR in D2O, respectively. For NMR analysis, 6.5 mg of
lyophilized polymer was dissolved in 0.65 mL D2O and 1H-NMR spectra were recorded
21

using a 400 MHz Bruker Avance NEO spectrometer equipped with a smart probe. A
series of low percent modified zPEIs ranging from 2-11.5% modification of the total PEI
amines was used in this study.

bPEI25k: 1H-NMR δH (400 MHz, D2O, ppm). 2.6–3.3 (broad multiplet, PEI)
zPEI: 1H-NMR δH (400 MHz, D2O, ppm). 2.4-2.5 (broad singlet, 4H,–C2H4–COOH),
2.6–3.3 (broad multiplet, PEI), 3.3–3.6 (broad multiplet, 2H, PEI–CH2–NH–CO-C2H4–).
FT-IR ν (ATR, cm-1). 1635 (C=O; amide I), 1563 (N-H; amide II).

2.2.3

Evaluation of DNA binding by Electrophoretic mobility shift (EMSA) and

Ethidium Bromide (EtBr) Exclusion Assays
EMSA was utilized to assess DNA binding efficiency for the zPEIs used in this
study. 0.8 w/v % agarose gels were prepared by dissolving agarose in a 0.2 µm filtered
TAE buffer (40 mM Tris base, 20 mM acetic acid, 1 mM EDTA). 200 ng pUC19 plasmid
DNA (1 mg/mL) was used per well. Polyplexes were formed in 10 mM Tris (pH 7.5) by
addition of the appropriate amount of each zPEI polymer to achieve the desired
polymer/DNA weight ratio and diluted to a total volume of 12 µL. After mixing,
polyplexes were incubated for 45 mins at room temperature. Before gel loading, 2 µL of
6X loading dye was then added to each sample, mixed, then the samples were loaded
onto the gel. Electrophoresis was performed at 100V for 90 minutes. PEI-PEG2k samples
were prepared and loaded in a similar fashion. For visualization, gels were stained with
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ethidium bromide (0.5 µg/mL) after electrophoresis, and a BioRad ChemiDoc MP
Imaging system was used to image each gel using Image Lab software.
For EtBr exclusion assay experiments, stock solutions of calf thymus DNA
(ctDNA, 0.24 µg/µL) and EtBr (0.024 µg/µL) were prepared in 10 mM Tris-HCl (pH 7.5)
buffer. From the stock, 50 µL EtBr (1.2 µg) was mixed and incubated to 50 µL ctDNA
(12 µg), and then the volume was adjusted to 500 µL with 10 mM Tris-HCl. After
equilibrating at room temperature for 10 minutes, the required volume (and
concentration) of polycation equivalent to the desired polymer/ ctDNA weight ratio was
mixed to this solution and incubated for another 30 minutes before placing the sample
into a semi-micro quartz cell. The fluorescence emission decay was recorded on a
Thermo Lumina Spectrophotometer at λex = 520 nm and λem = 610 nm. The reduction in
fluorescence was recorded in terms of the relative fluorescence (%) = [(F-F0)/(FMax-F0)]
*100, where F is the emission intensity of sample, F0 is the emission intensity of ethidium
bromide and FMax is the emission intensity of DNA intercalated with ethidium bromide.

2.2.4

Dextran Sulfate Displacement Assay
zPEI polyplex stability was checked by dextran sulfate displacement. 200 ng

pUC19 samples were complexed with a fixed zPEI/DNA weight ratio of 2.0 at a total
volume of 5 µL in 10 mM Tris buffer at pH 7.5. This polycation/DNA weight ratio was
observed to be sufficient for complete DNA complexation for all zPEIs used in this study.
For PEI-PEG2k /DNA, a weight ratio of 5.0 was required for complete complexation of
the DNA. Polyplexes were well mixed and incubated for 45 min at room temperature to
ensure complete DNA complexation. Dextran sulfate (DS) was then added at various
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weight ratios relative to the DNA and the final solution volume was brought up to 12 µL
by addition of buffer. Samples were subsequently incubated for an additional 30 minutes
to allow plasmid DNA release from the polyplexes. 2 µL loading dye was then added to
each sample followed by sample loading onto a 0.8% agarose gel and electrophoresed as
described above. PEI-PEG2k samples were prepared and loaded similarly. DNA was
visualized by post-run staining with ethidium bromide (0.5 µg/mL) and imaged using the
BioRad ChemiDoc MP Imaging System.

2.2.5

Particle size and ζ-potential analysis
The particle sizes for bPEI/DNA, zPEI/DNA and PEI-PEG2k/DNA polyplexes

was measured by nanoparticle tracking analysis (NTA) using a Nanosight NS300.
Polyplexes were prepared with 0.1 µg pUC19 plasmid DNA at the desired polymer/DNA
weight ratio in 200 µL of double distilled water (ddH2O) resulting in a 0.5 µg DNA/mL
solution. All samples were further diluted 1:5 with ddH2O and subjected to NTA analysis.
A 180s movie containing the Brownian motion tracking of the polyplex nanoparticles was
recording using the NTA image analysis software (Version 3.4). Each polyplex sample
was repeated three times with freshly injected samples and the resulting particle
diameters are reported as the arithmetic mean ± standard deviation.
Zeta potential measurements of polyplexes were performed on a Malvern
Instruments Zetasizer (Nano-ZS90) at a 15° scattering detector angle. Polyplexes were
formed using 2 µg pUC19 DNA (0.1 mg/mL) and mixed at the desired weight ratio with
condensing polymer. Samples were diluted to 1mL total for a final DNA concentration of
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2 ng/µl before zeta analysis. Zeta potentials were recorded 3 times each and are reported
as mean ± standard deviation.

2.2.6

Polyplex Transfection
HeLa and HEK293 cell lines were cultured in DMEM supplemented with 10%

FBS according to ATCC recommendations. Cell lines were seeded in 24-well plates at 7.5
x 104 cells/well 24 h prior to transfection. Polymer/DNA complexes were formed by
diluting 20 μL of 0.1 μg/μL DNA solution with 80 μL of phosphate-buffered saline (PBS)
in a 1.5 mL microcentrifuge tube. Polymer solutions (100 μL) at various concentrations
were added dropwise to the DNA solution under constant agitation to achieve the desired
polymer/DNA weight ratio. Particles were allowed to incubate at room temperature for
30 min. Immediately before transfection, 200 μL polyplex solution was deposited into 2.8
mL of serum-present medium. Regular growth medium was aspirated from cells and
replaced with 750 μL of polyplex/growth medium solution (0.5 μg DNA/well). After 4 h,
the transfection medium was replaced with normal growth medium. Transfection
efficiency was quantified via luciferase expression 24 h post initial transfection. A
Promega luciferase assay kit (Madison, WI) was used to measure protein activity in
relative light units (RLU) using a Synergy 2 plate-reader (BioTek, Winooski, VT).
Results were normalized to total cell protein using a bicinchoninic acid (BCA) assay
from G-Biosciences (St. Louis, MO).
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2.2.7

CRISPR/Cas9 Knock-In
Knock-In efficiency of zPEI 2 was evaluated by utilizing a dual plasmid

transfection system from Origene (Rockville, MD). The first plasmid, pCas-GuideAAVS1, encodes the Cas9 enzyme and a guide RNA that targets the AAVS1 region on the
genome, while the second plasmid, pAAVS1-Puro-GFP-DNR, encodes for the donor
DNA that carries an expressible GFP region. The donor DNA targets the AAVS1 region
using 500 base pair left and right homology arms. HEK293 cells were seeded in 6-well
plates at 3.0 x 105 cells/well 24 h prior to transfection. Polymer/DNA complexes were
formed by diluting 160 μL of 0.1 μg/μL DNA solution containing of 1:1 ratio of the Cas9
and donor DNA plasmids with 500 μL of PBS in a 1.5 mL microcentrifuge tube.
Lipofectamine 2000 solution was prepared according to manufacturer protocol. zPEI 2
and bPEI solutions were prepared using the optimum weight ratios determined by
luciferase transfection described previously. Equi-volume polymer or Lipofectamine
solutions were added dropwise to the DNA solution under constant agitation to achieve
the desired carrier/DNA weight ratio. Particles were allowed to incubate at room
temperature for 30 min. Immediately before transfection, 1.32 mL polyplex solution was
added to 10.68 mL of DMEM with or without 10% FBS. Growth medium was aspirated
from cells and replaced with 3 mL of polyplex/growth medium solution (4 μg
DNA/well). Transfection was allowed to proceed overnight. The following morning,
transfection media was aspirated and replaced by regular growth media. Cells were
allowed to grow for 48 h undisturbed, before being seeded in T75 flasks. Cells were then
passaged twice over the course of two weeks to eliminate any transient expression. Cells
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were analyzed for GFP expression via FACS on a LSR II flow cytometer (BD
Biosciences, Franklin Lakes, NJ).

2.2.8

Fluorescent Imaging of GFP
In order to visualize GFP production, transfected cells were subjected to

fluorescent microscopy via a Cytation 7 Cell Imaging Multi-Mode Reader
(BioTek,Winooski, VT). Cells were transfected as previously described and allowed to
passage twice before being seeded into an eight-chamber Lab-Tek II slide at 3.0x104
cells/well. Cells were allowed to grow for 24 h before being live stained with Hoechst
33342 nucleus stain (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
Immediately after staining, cells were imaged live using a widefield integrated
microscope with a 10x objective. Hoechst 33342 and GFP were visualized using filter
cubes with an excitation/emission of 377/447 and 469/525, respectively.

2.2.9

Protein Interaction Study
The affinity for nonspecific protein binding interactions was assessed by mixing

0.5 mL of bovine serum albumin (BSA) standard (2 mg/mL) with 0.5 mL of each
polymer (1 mg/mL). Each mixture was incubated at 37 °C for 1 h. The mixtures were
then centrifuged, and samples of the resulting supernatants were collected. The protein
concentrations of the samples were determined through the use of a BCA assay and a
standard BSA calibration curve. The protein interaction value, A, was defined as:
𝐴𝐴 = 1 −

27

𝐶𝐶𝑠𝑠 𝑉𝑉𝑠𝑠
𝐶𝐶𝑖𝑖 𝑉𝑉𝑖𝑖

where Ci is the initial BSA concentration (2 mg/mL); Cs is the BSA concentration in the
supernatant determined by BCA; Vi is the initial volume of the BSA solution (0.5 mL);
Vs is the total volume of the BSA after adsorption measurement (1 mL). The interaction
value A, as it has been described, is essentially a measure of how much protein has been
removed from the initial solution via aggregation with polymer, and thus, ranges between
0 (no removal of protein) and 1 (complete removal of protein).

2.3
2.3.1

RESULTS AND DISCUSSION
Synthesis and characterization of minimally succinylated PEIs (zPEIs)
As the objective of this study was to investigate the gene delivery efficacy of

sparsely modified bPEI via conjugation to succinic anhydride and subsequently compare
the ‘shielding abilities’ with commercial PEI-PEG2k, a series of minimally functionalized
zwitterion-like PEI (zPEI) was synthesized. Strategies for the modification of branched,
25-kDa PEI were adapted from our previous work (Figure 2.1a).99 By varying the feed
mole percentages of succinic anhydride with respect to the total amine content of PEI, we
controlled the percent modification of total amines of the zPEIs to the range of 2-11.5%
as determined by 1H-NMR and confirmed by FT-IR. Some cloudiness was observed in
the zPEI product solutions due, presumably, to aggregation of the polymer product under
the basic conditions used to synthesize the zPEIs. To improve solubility, the zPEIs were
clarified by addition of small amounts of 0.1 M HCl to near neutral pH (pH ~7). All
NMR and FT-IR spectra are shown in the supporting information (Figure 2.8-2.9). Upon
succinylation, two characteristic new peaks at 1635 cm-1 and 1563 cm-1 are

28

Figure 2.1. (a) Synthesis scheme for zwitterionic-like PEIs (zPEIs) via succinylation of
primary and secondary amines of a 25-kDa branched PEI polymer. (b) representative
1H-NMR spectra of bPEI and zPEI after neutralization to pH 7. Shown are 6.5%
functionalized zPEI (zPEI-6.5, top) and unmodified bPEI (bottom).

observed by FT-IR for all zPEIs due to the carbonyl stretch and N-H bend, respectively,
of the amide moiety of the succinyl group grafted to the PEI polymer. While all of the
PEIs have a characteristic set of methylene proton base peaks at 2.6 to 3.3 ppm by 1HNMR, upon succinylation two sets of new peaks are also observed as described above in
Methods and Materials. The degree of modification was subsequently analyzed and
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quantified by 1H-NMR from the ratio between methylene of PEI (δ 2.6-3.3 ppm) and
methylene of the succinyl group (δ 2.4-2.5 ppm). In Figure 2.1b, we show the 1H-NMR
spectra of unmodified bPEI (lower) compared to 6.5% modified zPEI (zPEI 6.5, upper)
where the degree of modification was expressed as the percentage of the total amines in
bPEI that were succinylated.

2.3.2

zPEI complexation of DNA
A prerequisite for effective gene delivery is the ability to assemble stable

polyplexes. The complexation of DNA by polycations occurs by entropically driven
electrostatic interactions.100 The ability of the minimally modified zPEIs to condense
plasmid DNA was assessed using both electrophoretic mobility shift assay (EMSA)
(Figure 2.2a) and EtBr exclusion assays (Figure 2.2b). Compared to bPEI, nearly all
succinylated zPEIs (≥ 3% modified) required higher polymer:DNA weight ratios to fully
retard DNA migration in agarose gel electrophoresis (Figure 2.2a). The required
polymer:DNA weight ratio increased with the percent modification of the PEI,
presumably due to the reduction of the positive charge density upon conjugation to the
succinyl group. Higher degrees of modification resulted in more zPEI being required to
fully bind the DNA. For example, unmodified PEI required a bPEI/DNA ratio 0.375
(wt/wt) in good agreement with prior literature101. In contrast, to fully condense the
DNA, zPEI 3, 6.5, 9, and 11.5 required polymer/DNA ratios of 0.625, 0.625, 0.75, and
1.125 (wt:wt), respectively. No significant difference in DNA binding between PEI and
zPEI 2 was observed.
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The influence of succinylation on the ability of zPEI to condense DNA was
further investigated by ethidium bromide exclusion assay (Figure 2.2b). Upon
intercalation between DNA base pairs, the fluorescence intensity of EtBr increases
significantly. Condensation of DNA by the binding of polycations prohibits binding of
EtBr, leading to a corresponding drop in the fluorescence intensity. All the polycations
displayed similar sigmoidal condensation curves. zPEIs were able to fully condense calf
thymus DNA to the same extent as unmodified bPEI, as evidenced by the same residual
relative fluorescence, at sufficiently high polymer/DNA ratios. The EtBr exclusion assay
curves shifted to higher polymer/DNA ratios with increasing degree of succinylation. All
zPEIs studied (2-11.5% modified) achieved condensation by polymer/DNA ratio 1
(wt/wt). These polymer/DNA ratios required for full condensation by EtBr exclusion
assays were often found to be slightly higher than those observed by EMSA, suggesting
an effect of the applied electric field on the migration of the plasmid DNAs in the agarose
gels.
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Figure 2.2. Polyplex complexation and stability assessment. (a) Evaluation of pUC19
plasmid DNA complexation with unmodified bPEI and zPEI (2-11.5%) by
electrophoretic mobility shift assay (EMSA). Complete retardation for all polycations
was achieved by polymer/DNA weight ratio of 1.0. The number above each lane
signified the polymer/DNA wt/wt ratio used to form each corresponding polyplex.
Uncomplexed DNA control is also shown. (b) DNA condensation by unmodified bPEI
and zPEI (2-11.5%) as determined by an ethidium bromide exclusion assay measured at
λex = 520 nm and λem = 610 nm. Calf thymus DNA (ctDNA) was used for all polyplexes.
The fluorescence intensity was expressed as a percentage relative to the initial
fluorescence. Data are presented as mean +/- SD (n = 3). (c) Dextran sulfate (DS)
displacement assay of bPEI and zPEI complexes formed at polymer/DNA weight ratio
2:1 analyzed by agarose gel electrophoresis. As percent modification increases, the
binding strength of zPEI decreases requiring less DS to displace the DNA from the
polyplexes. Shown are pUC19 plasmid DNA complexed with unmodified PEI (bPEI) and
zPEI 2, zPEI 6.5, and zPEI 9. The first lane is a control (C, free DNA) while the numbers
above each lane represent DS:DNA weight ratio.
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2.3.3

Dextran sulfate displacement assay
For transcription to occur, polyplexes must be able to dissociate into free DNA

and polymer upon entering the cell. This creates a well-known bottleneck for polyplexes
requiring balancing of the polymer-DNA interactions to create particles that are
sufficiently stable to reach cells but not too stable as to prevent dissociation inside the
cell. To investigate how these low degrees of succinylation alter complex stability in our
zPEI polyplexes, we evaluated the stability of our particles to a competing polyanion, the
sulfated polysaccharide dextran sulfate (DS, 9-20 kDa). DS mimics sulfated extracellular
glycosaminoglycans (GAGs), such as heparan sulfate, that are well known to
competitively displace DNA from cationic polymers in polyplexes in vivo.102 The relative
strength of polymer-DNA interactions can be quantified by determining the ability of DS
to displace polycation from DNA. Unmodified bPEI and zPEI polyplexes were prepared
at polymer/DNA ratio 2 (wt/wt) sufficient to completely condense DNA for all zPEIs
studied, and subsequently incubated with DS at various concentrations. Polyplex
dissociation was followed by agarose gel electrophoresis (Figure 2.2c). With increasing
succinylation, we observed a systematic decrease in the amount of DS required to release
DNA in the zPEI series. Unmodified bPEI required 7 µg DS/µg DNA to completely
displace DNA from its polyplex, while 3.4, 3.0 and 1.0 µg DS/µg DNA were required for
the onset of DNA release with zPEI 2, 6.5 and 9, respectively. For minimally modified
zPEI, the release of DNA was not always complete on the gel. This incomplete release
was not observed for unmodified bPEI or previously studied highly modified zPEIs. This
suggests the sparsely modified zPEIs are maintaining some weak interaction with the
polyplex DNA even in the presence of excess polyanion competitor. However, the
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amount of DS required for onset of DNA release still decreased in a systematic way with
increasing degree of modification, consistent with a weakening of the polymer-DNA
interactions with increasing amounts of grafted anionic succinate groups to the PEI
backbone.

2.3.4

Characterization of PEI-PEG Polyplex complexation and stability
In our previous study with high percent modified zPEIs (9-55%), we observed

that succinylation led to a substantial decrease in nonspecific protein binding. We
proposed this reduced affinity for protein interactions may result from the formation of a
tightly bound hydration layer due to the assumed zwitterionic nature of the polyplex
surface. This tightly bound water layer thus acts in a fashion similar to more commonly
used strategies to incorporate shielding domains, such as PEG, to polyplex formulations.
We were therefore interested in directly comparing our minimally functionalized zPEI
series to PEGylated PEI. To investigate the effects of PEGylation on PEI condensation of
DNA, we compared unmodified 25-kDa bPEI to PEI-PEG2k copolymer by a mobility
shift assay (Figure 2.3a). Here, the PEI-PEG2k is a graft copolymer of 25-kDa, branched
PEI modified with 2-kDa PEG at a 10% substitution ratio of primary amines. Unmodified
bPEI is observed to fully condense DNA at a polymer/DNA weight ratio 0.5. Assuming
the theoretical 25:50:25 ratio of primary, secondary, and tertiary amines for bPEI, we can
estimate the 10% substitution on PEI results in ~15 PEG chains per PEI molecule
resulting in a total polymer MW for PEI-PEG2k of ~55 kDa. Some experiments have
shown commercial bPEI may have closer to a 33:33:33 ratio of primary, secondary, and
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Figure 2.3. (a) Electrophoretic mobility shift assay (EMSA) of 200 ng pUC19 plasmid
complexed with bPEI and PEI-PEG2k. Numbers above the lanes signify the
polymer/DNA weight ratio used to form each corresponding polyplex. The leftmost lane
is uncomplexed pUC19 DNA as control. (b) dextran sulfate (DS) displacement assay for
bPEI and PEI-PEG2k complexes formed at polymer/DNA weight ratio 5. Control-1 is
pUC19 with no polycation present, while control-2 is polymer/DNA complex with no DS
present. Numbers above the lanes designate the DS:DNA weight ratio.
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tertiary amines.103 This ratio at 10% substitution would result in ~19 PEG chains per PEI
resulting in a total MW for PEI- PEG2k of ~63kDa. If we only consider the PEI part of the
copolymer, and assume the PEG is not altering the PEI:DNA interactions, we would
expect full condensation of PEI-PEG2k by polymer/DNA weight ratio of 1.1-1.25.
Instead, we observe the PEI-g-PEG2k does not achieve full complexation until
polymer/DNA weight ratios > 3. This suggests the PEG is sterically hindering the
polycation interactions with DNA, altering the polymer-DNA interactions in the
polyplexes. This is consistent with prior reports that suggest a complex relationship
between PEGylation and transfection efficacy that can depend on PEG MW and percent
substitution.104 We also examined the effect of PEGylation to alter the complex stability
in PEI- PEG2k polyplexes when compared to unmodified bPEI/DNA using the dextran
sulfate displacement assay (Figure 2.3b).
As the PEGylated PEI required more polymer to achieve full condensation, the
displacement assay was done at the higher polymer/DNA weight ratio of 5 for both bPEI
and PEI-PEG2k. At this higher polymer/DNA ratio, unmodified bPEI released DNA from
its complex at 15 µg DS/µg DNA, while PEI-PEG2k required only ~2 µg DS/µg DNA for
significant release of its DNA. This release occurred at DS/DNA ratios significantly
lower than expected even if we only consider the PEI component of the copolymer, again
consistent with the PEG greatly reducing the PEI-DNA interaction strength, thus reducing
the polyplex stability.
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2.3.5

Particle size and zeta potential measurement
Polyplex size and zeta potential are known to be key parameters that dictate

transfection performance. To better understand how bPEI, zPEI and PEI-PEG2k polyplex
particles differ, we measured their size by nanoparticle tracking analysis (NTA) at
polymer/DNA weight ratios sufficient for complete DNA condensation. Results are given
in Table 2.1. As shown, bPEI/DNA (wt/wt 0.5) results in nanoparticles exhibiting a mean
size of 97.5 ± 10 nm and a zeta potential of +12.3 mV indicating compact polyplex
formation with a positive surface charge. In general, the minimally modified zPEI
polymers at weight ratio 1, all produce polyplexes with nearly the same mean size with a
small increase observed for the highest modified zPEI studied. The zeta potential of the
low percent modified zPEI polyplexes decreased slightly compared to unmodified
bPEI/DNA. 2-11.5% modified zPEI resulted in nanoparticles with zeta potential of ~1011 mV compared to 12.3 for unmodified bPEI/DNA and no clear trend with increasing
percent modification. Since the addition of the succinyl group to zPEI is expected to both
neutralize
Table 2.1. NTA analysis and ζ-potential of polyplexes. Data presented as mean ± SD (n
= 3)
Polymer: Polyplex
ζ-potential
DNA
Diameter
(mV)
(wt:wt)
(nm)
PEI
zPEI 2
zPEI 6.5
zPEI 9
zPEI 11.5
PEI-PEG2k

0.5:1
1:1
1:1
1:1
1:1
5:1

97.5 ± 10
101.5 ± 17
102.7 ± 25
103.7 ± 3
112.6 ± 4.7
118 ± 5.3
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12.3 ± 0.9
11 ± 2
11 ± 1.43
10.4 ± 1.4
11.2 ± 1.0
4.81 ± 1.6

a positive charge while simultaneously adding a negative charge, this minimal impact on
the zPEI polyplex surface charge is surprising but consistent with our prior study.99 One
possible explanation for this is that the addition of a succinyl group onto a PEI amine
may increase the pKas of neighboring amines resulting in a net charge on the zPEIs
comparable to bPEI. Previously, we showed that only at very high percent modification
(>40%) did we observe significant decrease in zPEI polyplex zeta potential. PEGylation
of polyplexes is well known to typically result in a decrease in the particle zeta potential
due to PEG shielding the positive surface charge of PEI. Here, we determine the mean
particle size and zeta potential for our PEI-PEG2k/DNA particles at weight ratios
sufficient for complete DNA condensation (wt:wt 5). We observe slightly larger
polyplexes (mean diameter ~118 +/- 5 nm) but a significant decrease in the particle zeta
potential (z = 4.81mV) when compared to bPEI or zPEI polyplexes.

2.3.6

In-Vitro Transfection Efficiency
In previous studies, we and others showed that succinylation of PEI results in

modest improvement of transfection of DNA in the absence of serum.98-99 In contrast, we
see significant improvement in transfection efficacy in the presence of serum for
zPEI/DNA polyplexes. This improvement is such that zPEI efficacy in the presence of
serum was observed to meet or exceed transfection of unmodified bPEI in the absence of
serum. In our previous study of more highly modified zPEIs,99 we found the lowest
percent modifications studied (9-25%) were the most effective for gene delivery to HeLa,
MC3T3-E1 and MDA-MB-231 cells. To further study the effectiveness of zPEIs, we
study here a series of sparsely modified zPEIs (2-11.5%) to determine both a minimum
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modification needed for enhanced transfection as well as the range of modifications
resulting in maximum gene delivery improvement. For this study, two cell lines (HEK
293 and HeLa) were transfected with polyplexes of unmodified PEI, minimally
functionalized zPEIs, and PEI-PEG2k to determine gene expression in the presence of
serum at various polymer/DNA ratios (Figure 2.4). Unmodified PEI exhibited a nearly
constant level of gene expression under the polymer/DNA weight ratio range of 1:1 to 6:1
for both cell lines. The minimally modified zPEIs (2-11.5%) generally all show
significantly improved transgene expression at nearly all weight ratios in both cell lines.
Remarkably, even PEI succinylated at levels as low as 2% still show this significant
enhancement of the transgene expression in both cell lines upon transfection in the
presence of serum. Here, maximum gene expression for zPEI was observed at
polymer/DNA weight ratio 2:1 and 4:1 for HEK293 and HeLa cells, respectively.
Comparing these maximum transfection efficiencies, zPEI 2 exhibited 477-fold higher
gene expression in HEK293 cells (Figure 2.4a) and 262-fold in HeLa cells (Figure 2.4b)
as compared to unmodified PEI. While an optimal modification percent was not clear, we
see a broad range of 2-10% modification results in the maximal gene expression in the
presence of serum for zPEIs. In nearly all transfections, zPEI efficacy is observed to
decrease at modifications higher than 10%. Yet even the highest modification studied in
this manuscript (zPEI 11.5) at polymer/DNA weight ratio 2:1 exhibited 85- and 143-fold
higher gene expression as compared to maximum gene expression of unmodified bPEI in
HEK293 and HeLa cell lines, respectively.
Lastly, we compared zPEI to a commercially available PEI-PEG2K to directly
compare in-serum transfection efficiencies. PEGylation is known to decrease interaction
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Figure 2.4. In vitro transfection efficiency of polyplexes of plasmid DNA (pGL3) with
unmodified, PEGylated, and succinylated PEI in (a) HEK293 and (b) HeLa cells in the
presence of 10% FBS. Luciferase activity in the cell lysates is reported as relative light
units (RLU) normalized by the mass of total protein in the lysate. (n = 3; error bars
represent standard deviation.)
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of the polymers with serum proteins, often resulting in decreased toxicity and improved
biodistribution compared to unmodified PEI.104 We previously showed higher degrees of
succinylation of PEI also results in decreased toxicity and reduced interactions with
proteins.99 For transfections in-serum, the maximum gene expression of PEI-PEG2k was
found to occur at polymer/DNA weight ratio 5:1 for both HEK293 and HeLa cell lines
(Figure 2.4). When compared to unmodified PEI, the transgene expression is found to be
only 5- to 7-fold higher. In comparison to PEI-PEG2k, zPEI 2 exhibited 65- and 53-fold
higher transgene expression in HEK 293 and HeLa cells, respectively, at polymer/DNA
weight ratio 2:1. PEI-PEG2k at polymer/DNA weight ratio of 1 was not used in this study
as the previous binding assays (Figure 2.3) showed PEI-PEG2k did not sufficiently bind
DNA to form polyplexes at this weight ratio.

2.3.7

CRISPR/Cas9 Knock-In Efficiency
CRISPR/Cas9-mediated knock-in of genes by homology-directed recombination

typically requires simultaneous expression of Cas9, transcription of a single guide RNA
(sgRNA), and delivery of a “donor” plasmid containing the gene sequence to be
introduced. The efficiency of knock-in is often very poor (less than 1%), especially in
primary cells or in vivo.105 Knock-in in such cases may be more efficient, and cell
viability may be better preserved, if efficient transfection of the CRISPR/Cas9
components could be achieved in the presence of serum. Thus, we investigated knock-in
efficiency in HEK293 cells using zPEI 2 to co-deliver a plasmid that encodes Cas9 and a
sgRNA targeting the AAVS1 locus, and a donor plasmid that encodes GFP, both in the
absence and presence of serum, in comparison to bPEI and Lipofectamine 2000 (L2k).
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Transfections with zPEI 2 resulted in significantly higher percentages of GFP-expressing
cells than PEI and L2k in both the presence and absence of serum (Figure 2.5). Knock-in
efficiency, quantified as the percentage of GFP-positive cells determined by flow
cytometry (Figure 2.6), was two- and 1.6-fold greater upon transfection in the absence of
serum with zPEI 2 compared L2k and bPEI, respectively. In the presence of serum,
however, knock-in efficiency with zPEI 2 increased slightly. Transfection with L2k and
bPEI, in contrast, decreased significantly in the presence of serum. As a result, zPEI 2
provided a remarkable 16-fold increase in the knock-in efficiency compared to both
controls. The increased knock-in efficiency with zPEI 2 in the presence of serum than in
its absence may be attributed to deleterious effects upon incubation of the cells in the
absence of serum overnight, which may be expected to decrease cell viability. In many
protocols, the decrease in viability (and, thus knock-in efficiency) due to the absence of
serum is outweighed by the severe decrease in transfection efficiency observed with
many conventional transfection reagents in the presence of serum. Using zPEI 2,
however, we achieved efficient transfection while maintaining cell viability (Figure
2.10).
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Figure 2.5. Confocal fluorescence micrographs of HEK293 cells transfected with a dualplasmid CRISPR/Cas9 system to knock in GFP, mediated by Lipofectamine 2000, bPEI,
or zPEI 2, in the absence and presence of serum. Cell nuclei were stained with Hoechst
33342(blue). Scale bar = 300 µm.
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Figure 2.6. Flow cytometry of HEK293 cells following CRISPR/Cas9-mediated knockin of GFP upon transfection using L2k, bPEI, and zPEI 2 in (a) the absence and (b) the
presence of serum. (c) Knock-in efficiency as determined by the percentage of GFPexpressing cells. Cells were allowed to grow normally for two passages to eliminate any
transient GFP expression. (n=3; error bars represent standard deviation).
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2.3.8

Interaction of Polymers with Serum Proteins
To further evaluate the relative stabilities of our different polymer systems in the

presence of serum proteins, we quantified the ability of bPEI, zPEI and PEGylated PEI to
aggregate bovine serum albumin (Figure 2.7). At physiological pH, most serum proteins
are anionic. Due to the low isoelectric point of bovine serum albumin (BSA, pI = 4.7), it
remains anionic under physiological conditions and thus serves as a model serum
protein.106 All polymers were incubated with 2 mg/mL BSA for 1 h. This protein

Figure 2.7. Protein interaction values of free polymers incubated with BSA standard for
1 h. Interaction values were expressed as the percentage of protein adsorbed per weight
of polymer determined through the difference in protein concentration before and after
incubation. (n = 3; error bars represent standard deviation).
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concentration is comparable to the anionic protein concentration in growth media
containing 10% serum. Unmodified PEI interacts most strongly with BSA, resulting in
the highest observed interaction values. PEI-PEG2k shows a strong decrease in the protein
interaction due, presumably, to the reduced net charge and steric hindrance of the grafted
PEG chains. For our minimally modified zPEIs, we only see a significant decrease at
succinylation levels ≥ 9%. Zwitterionic materials, with equimolar amounts of positive
and negative charges on the same chain, have been extensively studied for nonfouling
applications. These systems are thought to resist nonspecific protein binding due to a
tightly bound water layer with the zwitterionic surface that forms a physical and energetic
barrier to adsorption of proteins.107-108 The very low degree of succinylation for the zPEIs
studied here would suggest the resulting polyplexes are unlikely to have sufficient
positive and negative surface charges to form such a tight water layer. The high efficacy
of sparsely modified zPEIs such as zPEI 2, in which only ~12/581 PEI amines have been
functionalized, is thus highly surprising. From binding and competition assays, zPEI 2
seems to bind and release DNA in a similar fashion to unmodified PEI. Previously, we
observed in HeLa, MDA-MB-231 and MC3T3-E1 cell lines that higher levels of
succinylation (>14%) were required to significantly decrease cytotoxicity of the zPEIs.99
In addition, the cellular uptake for the best performing zPEIs (9-25%) in that
study were not significantly higher than unmodified bPEI. From Figure 2.7, we also see
zPEI 2 gene expression in serum is not correlated to reduced nonspecific protein
interactions. Recently Zhu et al.109 showed that proteins such as BSA can adsorb onto PEI
polyplexes to form a protein corona, significantly altering the gene delivery activity of
the complexes. Similarly, the low-percent-modified zPEIs may alter the adsorption of
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serum proteins onto the zPEI complexes relative to unmodified PEI polyplexes, which
may explain the significant enhancement of zPEIs in the presence of serum. Another
possible explanation is the succinylation of zPEI may trigger a response from the
succinate ligand-receptor on the cell surface, possibly leading to uptake by
macropinocytosis or another internalization pathway leading to increased transgene
expression.110-111 Further investigations into uptake pathways for zPEI are currently
underway.

2.4

CONCLUSION
We have synthesized a series of minimally succinylated polyethylenimines to

determine their transfection efficacy and biocompatibility in the presence of 10% serum.
The introduction of negatively charged succinate group neutralizes a small fraction of
amines resulting in decreased polymer/DNA binding ability but retaining transfection
efficiency. Overall, the key finding from this study is that succinylation of PEI on as few
as 2% of amines provides significant improvements in gene delivery. Maximum
transfection efficacy was observed at ~2-10% modification with a significant decrease in
transfection efficiency for zPEI with succinylation higher than 10%. These minimally
(<10%) modified zPEIs, all exhibited 220-fold to 490-fold improvement in transgene
expression in the presence of serum as compared to that of unmodified bPEI and more
than 50-fold higher efficacy than commercial PEI-PEG2k polyplexes in both HEK293 and
HeLa cell lines. Furthermore, zPEI 2 allowed highly efficient knock-in of a marker gene
in the presence of serum, which may provide a significant advantage in CRISPR-
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mediated genome editing in difficult-to-transfect cells. Tuning positive charge density of
a polymer vector is thought to be crucial to optimize serum stability and electrostatic
interaction with proteins on the cell membrane to initiate endocytosis. However, the
protein interaction for our minimally modified zPEIs does not correlate with the
transfection efficacy, suggesting that reduced adsorption of serum proteins on polyplexes
is not the critical factor for a successful transgene polyplex carrier.
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2.5

Supplementary Information

2.5.1

Synthesis of polymers

zPEIs were synthesized using the protocol from our previous work by Warriner et.al.
(2018). Half a gram of branched PEI (bPEI, 25kDa) was dissolved in 3 ml bicarbonate
buffer (0.1 M, pH 9) and reacted with succinic anhydride at different mole ratios for 4
hours at 60 °C. The reaction mixture was then dialyzed with snakeskin dialysis tubing
(3.5 kDa MWCO) in double distilled water for 24 hours changing the water every 4
hours. After dialysis, the products were filtered with 0.22 μm PVDF membrane filter,
then frozen overnight and lyophilized for another 24 h. Upon re-dissolving, the zPEI
solutions were often observed to have some cloudiness that was not removed with
filtering. To improve solubility, the zPEI polymers were subsequently buffered to pH 7
by addition of HCl (0.1M) clarifying the solution. After acidification, the product was
frozen overnight and lyophilized again for 24 hours. The dried product was placed in a 80 °C freezer for storage. Successful reaction and percent succinylation were
subsequently determined by FT-IR and 1H NMR, respectively.

2.5.2

Fourier transform infrared (FTIR)
FTIR analysis of bPEI and all zPEIs were collected to confirm the polymer

modification using an iS50 FT-IR equipped with a diamond ATR within the range 4004000 cm-1 equipped with OMNIC software. Upon successful coupling reaction of the
bPEI with succinyl anhydride to form zPEI, characteristic peaks at 1563 cm-1 and 1635
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cm-1 are seen corresponding to the carbonyl stretch and N-H bend of the amide,
respectively. FTIR spectra are given in Figure 2.8.

Figure 2.8. The FTIR spectra of unmodified bPEI and zPEI (2-11.5% modified)
polymers.

2.5.3

NMR characterization of bPEI and zPEI
To quantify the degree of modification of the polymers, 1H-NMR characterization

was conducted on a 400 MHz Bruker Avance NEO spectrometer equipped with a smart
probe. For NMR analysis, 6.5 mg of lyophilized polymer was dissolved in 0.65 mL D2O
and data was analyzed with Topspin 4.0.3 data analysis software. NMR spectra are given
in Figure 2.9. The relative area of succinate methylene peaks (δ 2.4-2.5 ppm) was
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compared to the peaks of branched PEI methylene protons (δ 2.6-3.3 ppm) to determine
the degree of modification of zPEIs.

Figure 2.9. 1H NMR of unmodified bPEI and zPEI (2-11.5% modified).

2.5.4

Toxicity of Serum Deprivation
HEK293 cells were seeded in 24-well plates at 7.5 x 104 cells/well 24 h prior to

transfection. Polymer/DNA complexes were formed by diluting 20 μL of 0.1 μg/μL DNA
solution containing of 1:1 ratio of the Cas9 and donor DNA plasmids with 80 μL of PBS
in a 1.5 mL microcentrifuge tube. Lipofectamine 2000 solution was prepared according
to manufacturer protocol. zPEI 2 and bPEI solutions were prepared using the optimum
weight ratios determined by luciferase transfection described previously. Equi-volume
polymer or Lipofectamine solutions were added dropwise to the DNA solution under
constant agitation to achieve the desired carrier/DNA weight ratio. Particles were allowed
to incubate at room temperature for 30 min. Immediately before transfection, 200 mL
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polyplex solution was added to 2.8 mL of DMEM with or without 10% FBS. Growth
medium was aspirated from cells and replaced with 0.75 mL of polyplex/growth medium
solution (0.5 μg DNA/well). Transfection was allowed to proceed overnight. The
following morning, transfection media was aspirated and replaced by regular growth
media containing CellTiter-Blue metabolic dye. Cells were allowed to incubate for 4 h at
37 °C and 5% CO2. Then, cells were immediately excited with a 560-nm laser and the
fluorescence was read at 590 nm using a Synergy 2 plate-reader (BioTek, Winooski, VT).
Fluorescence was normalized to non-transfected cells under normal growth conditions.

Figure 2.10. Cytotoxic effects of extended serum deprivation on HEK293 cells during
transfection. Metabolic activity was assessed 16 h post introduction of polyplexes or
lipoplexes and normalized to the activity of untreated cells (n = 3, error bars represent
standard deviation).

2.5.5

CRISPR/Cas9 Knock-In
Knock-In of GFP into AAVS1 using zPEI 2 was verified by transfecting HEK293

cells with pAAVS1-Puro-GFP-DNR and pAAVS1-Puro-GFP-DNR in tandem with pCasAAVS1-Guide. The first plasmid, pAAVS1-Puro-GFP-DNR, encodes for the donor DNA
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that carries an expressible GFP region, while the second plasmid, pCas-Guide-AAVS1,
encodes the Cas9 enzyme and a guide RNA that targets the AAVS1 region on the
genome. The donor DNA targets the AAVS1 region using 500 base pair left and right
homology arms. Insertion into AAVS1 should only occur when the guide cassette is
present. HEK293 cells were seeded in 6-well plates at 3.0 x 105 cells/well 24 h prior to
transfection. Polymer/DNA complexes were formed by diluting 160 μL of 0.1 μg/μL
DNA solution containing either entirely the donor plasmid or a 1:1 ratio of the Cas9 and
donor DNA plasmids with 500 μL of PBS in a 1.5 mL microcentrifuge tube. The equivolume polymer solution was added dropwise to the DNA solution under constant
agitation to achieve the desired carrier/DNA weight ratio. Particles were allowed to
incubate at room temperature for 30 min. Immediately before transfection, 1.32 mL
polyplex solution was added to 10.68 mL of DMEM with 10% FBS. Growth medium
was aspirated from cells and replaced with 3 mL of polyplex/growth medium solution (4
μg DNA/well). Transfection was allowed to proceed overnight. The following morning,
transfection media was aspirated and replaced by regular growth media. Cells were
allowed to grow for 48 h undisturbed, before being seeded in T75 flasks. Cells were then
passaged twice over the course of two weeks to eliminate any transient expression. After
two weeks the cells were analyzed for GFP expression via FACS on a Symphony A3
flow cytometer (BD Biosciences, Franklin Lakes, NJ). Data is plotted in Figure 2.11.
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Figure 2.10. (Top) Cell micrographs displaying the GFP expression of untransfected
HEK293 and HEK293 that have been transfected with either the GFP donor plasmid
(pAAVS1-Puro-GFP-DNR) or the donor plasmid and cas9 guide cassette (pCas-GuideAAVS1) using zPEI 2 in the presence of serum. (Bottom) Histograms of FACS analysis
and the corresponding percentage of cells producing GFP displayed in a bar graph. Cells
were passaged twice over the course of two weeks after the initial transfection to
eliminate any transient expression. Cells were visualized and analyzed for GFP
expression via a Cytation 7 multimode plate reader and a Symphony A3 flow cytometer,
respectively.

CHAPTER 3. STRUCTURAL INVESTIGATIONS OF PEI AND MODIFIED PEI-DNA
COMPLEXES CORRELATING TO TRANSFECTION EFFICACY
Preface: This work was performed in collaboration with the group of Dr. Daniel Pack of
the Departments of Chemical & Materials Engineering and Pharmaceutical Sciences at
the University of Kentucky. All polymer design, synthesis and characterization, DNA
binding assays, dextran sulfate displacement, DLS, ζ-potential and SAXS measurements
were completed by the author in the lab of Dr. Jason DeRouchey. Gene transfection
experiments were performed by Levi Lampe in the laboratory of Dr. Daniel Pack.

3.1

INTRODUCTION
Gene therapy has gained significant attention in recent years as a potential

treatment for genetically intractable diseases, infectious diseases, neurodegenerative
diseases, and cancer owing to the advances in nucleic acid research both in biology and
chemistry. To date, most of the gene therapy clinical trials worldwide (~70%) are
conducted with recombinant viruses to deliver genetic materials due to their inherent
capacity for high efficiency in cell targeting as well as their ability to enter cells
efficiently.58,
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But viral gene delivery suffers from fundamental drawbacks such as

immunogenicity, oncogenicity, toxicity, and high production costs that have driven the
development of nonviral gene delivery alternatives.69 Unlike viruses, nonviral gene
delivery agents, such as cationic polymers, dendrimers, lipids, and peptides have several
advantages compared to the inherent limitations of viral vectors including lower cost and
flexibility in chemical modification. Although there is a lack of transferability compared
to a virus, nonviral vectors offer a way to better understand the key limiting steps in the
transfection process to create more efficient gene delivery agents.113
Among the first generations of nonviral alternatives, cationic polyethylenimine
(PEI) is considered a benchmark for polymeric, nonviral gene delivery vectors. PEI is

highly cationic and readily condenses DNA to create positively charged nanoparticles
capable of being taken up into cells for effecient gene delivery. In addition, branched PEI
(bPEI) has a large number of primary, secondary and tertiary amines that can both buffer
pH and provide sites for further chemical modification to potentially improve the
physicochemical and biological properties of the resulting PEI-DNA complexes.69, 114-116
Grafting functional domains to the PEI polymer backbone, such as shielding domains117119

, targeting ligands120, endosomolytic agents121, or multifunctional groups122-123 are

common strategies to improve gene delivery efficacy. Many of these modifications
ultimately reduce the net cationic charge of the PEI and have been shown to decrease the
cytotoxicity of PEI. For example, acetylation of a 25kDa bPEI was shown to reduce the
surface charge of the resulting polyplex particles and lower the buffering capacity
resulting in enhanced gene delivery and reduced vector cell toxicity.88-89 While
modifications neutralizing the PEI amine charge are relatively common, less studied has
been the incorporation of negatively charged moieties to generate polyampholytic
polymers. In 2008, succinylated PEI was shown to be an effective delivery agent for
siRNA.97 More recently, we and others have shown that succinylated PEI also results in a
modest improvement in serum-free transfections in vitro.98-99 Surprisingly, we also found
these succinylated, or zwitterionic-like, PEIs (zPEI) were especially beneficial for gene
delivery done in the presence of serum proteins that more closely mimics in vivo gene
delivery conditions.99 PEI polyplexes transfected in the presence of serum proteins is well
known to result in a significant decrease in transfection efficiency on the order of 10- to
100-fold. While high degrees of succinylation were not beneficial, we found that lower
levels of succinylation resulted in significant enhancement of transgene expression in the
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presence of serum that was comparable or even surpassed unmodified bPEI/DNA in the
absence of serum.99 More recently, we synthesized a series of minimally succinylated
zPEIs (2-11.5% modification) and found that succinylation levels <10% enhanced
transgene expression in the presence of serum proteins were beneficial in both HEK293
and HeLa cell lines,124 also found in Figure 2.5. Surprisingly even succinylation of only
2%, corresponding to ~12 of the 581 amines in 25kDa bPEI, was sufficient to both
enhance transfection as well as increase efficiency of CRISPR/Cas9-mediated knock-in
in the presence of serum proteins. Succinylating only 2% of PEI amines (zPEI 2) was
sufficient to enhance transgene expression 260-fold to 480-fold higher than unmodified
PEI in serum for HEK293 and HeLa cells, respectively. We also showed this same zPEI 2
polymer also enhanced the efficiency of CRISPR/Cas9 gene knock-in in both serum and
serum-free transfections. In the presence of serum, a 16-fold increase in CRISPR/Cas9
gene knock-in was observed for zPEI 2 when compared to unmodified PEI. Surprisingly,
this minimal succinylation did not significantly decrease the PEI interactions with serum
proteins nor the polymer-DNA interaction strength yet still was able to provide enhanced
transgene expression and gene knock-in when serum proteins are present. The successful
modification of PEI by both acetylation and succinylation are promising first steps but
also highlight the need for more fundamental understanding of the complex correlations
between polycation-DNA interactions and the resulting physiochemistry of the
polyplexes and transgene expression observed in cells. A better understanding of the
critical barriers to nonviral gene delivery are required to improve efficacy in vivo and
ultimately move nonviral vectors into clinical applications.
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In vitro experiments show that the condensation of DNA depends on the net
charge of the polycation.125 Due to the high charge, DNA helices in solution naturally
repel each other. In the presence of cations with valence +3 or larger, these repulsions can
be overcome and the polycation can effectively condense DNA.126 Through this selfassembly process, the resulting condensate has a compacted structure with DNA being
typically packaged in a columnar hexagonal lattice with well-defined equilibrium
separation between DNA helices. The separation of the helices is a result of the balancing
of short-range repulsions and long-range attractions in the system.127-129 Depending on
the polycation used, these DNA-DNA equilibrium spacings result in ~7-15 Å of water
separating the surface of neighboring DNA helices.129-130 To account for the attractions
driving DNA condensation, most models require a correlation of charges or water
structuring.131-132 For example, the electrostatic zipper model proposes that cations bind
in the major or minor grooves of DNA resulting in attractive interhelical correlations
between the bound positive charge of the cation and the negatively charged phosphate of
an apposing helix.133-135 Most structural studies of DNA condensation to date have
focused on metallic or linear polycations. There is experimental evidence suggesting
these polycations do bind in DNA grooves.136-138 Branched synthetic polymers, such as
PEI, presumably would not be able to bind and correlate their charges in the same manner
as linear polycations possibly requiring other binding modes, such as bridging, to induce
condensation. Despite its importance in polymeric gene delivery not much work has been
done to investigate how PEI and modifications of PEI alter the internal nanoscale
structuring of DNA within polyplexes.
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We have investigated the internal structure of polyplexes resulting from the
condensation of DNA with unmodified and modified branched PEIs as well as
determined their effectiveness as transfection agents in the presence of serum proteins.
Two series of modified PEI were synthesized by modification of 25kDa bPEI by either
acetylation (10-50%) or succinylation (2-40%). The acetylated PEI (acPEI) and
succinylated PEI (zPEI) were characterized by FT-IR and 1D- and 2D-NMR. Nearly all
modified PEIs were found to be capable of condensing DNA and inducing transgene
expression in HeLa cell line. SAXS experiments were performed to determine the
internal packaging of the resulting polyplexes. Both succinylation and acetylation
modifications resulted in decreased polycation-DNA interactions, suggesting more
loosely ordered structures. For acetylated PEI, SAXS experiments revealed that the interDNA spacings increase monotonically. zPEI however shows a crossover behavior where
DNA-DNA spacings increase at low degrees of modification but decrease again at higher
levels of succinylation. Time-course SAXS studies reveal small rearrangements in the
PEI and modified PEI polyplexes over time. Lastly, we show that pH has strong effects
on the resulting DNA packaging in all the PEI polyplexes. Specifically, condensing at
low pH (pH 4) results in tighter DNA packaging within PEI and modified PEI polyplexes
relative to polyplexes condensed at near neutral pH (pH 7.5). In addition, polyplexes
initially formed at pH 7.5 and then acidified show significant structural rearrangements
within one hour, resulting in a more highly packaged DNA. Polyplexes formed by both
modified PEIs show larger pH induced changes in the nanoscopic structure when
compared to the unmodified bPEI polyplexes.
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3.2

3.2.1

METHODS AND MATERIALS

Materials
Branched polyethylenimine (PEI, 25kDa), acetic anhydride, succinic anhydride,

dextran sulfate (9-20 kDa from Luconostoc spp), and highly polymerized calf-thymus
(CT) DNA sodium salt (molecular weight ∼10−15 million Da) were purchased from

Sigma-Aldrich (St. Louis, MO). The presence of protein impurities with the CT DNA

was checked by measuring the ratio of absorbance at 260 and 280 nm by UV/VIS. DNA
solutions were found to be satisfactory with A260/A280 ≥ 1.8. Ethidium bromide was
purchased from International Biotechnologies Inc. (Newhaven, CT), and D2O was
purchased from Cambridge Isotope Laboratories (Andover, MA). All other chemicals
were purchased from Thermo Fisher Scientific (Waltham, MA) and used without further
purification.

3.2.2

Synthesis and Characterization of succinylated and acetylated PEI
Succinylated (or zwitterion-like PEI, zPEI) and acetylated (acPEI) were

synthesized from unmodified branched PEI (bPEI) as follows. Half a gram of bPEI was
dissolved in 3 mL of 0.5 M sodium bicarbonate buffer (pH 9) and reacted the desired
mole ratio of either succinic or acetic anhydride. Succinic anhydride was added directly
as a dry powder, while acetic anhydride was added dropwise to the PEI solution. These
reactions then proceeded at 60 ºC for 4 hours and the crude product was filtered using a
0.22 μm PVDF syringe filter. Final modified PEI products were subsequently purified by
dialysis (membrane molecular weight cutoff = 3.5 kDa) against double distilled water for
48 hours with the water replaced every 4 hours. After dialysis, the products were frozen
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overnight and lyophilized for 48 hours. The dried product was placed in a -80 ºC freezer
for storage. A series of modified succinylated PEI (zPEI, 2-40%) and acetylated PEI
(acPEI, 10-50%) were synthesized.

Final modified PEI products were characterized by FT-IR (ATR) and 1D-NMR
and 2D-NMR (HSQC, HMBC). For NMR analysis, 6.5 mg of lyophilized polymer was
dissolved in 0.65 mL D2O and NMR spectra were recorded using a 400 MHz Bruker
Avance NEO spectrometer equipped with a smart probe. The degree of modification was
determined by 1H-NMR from the ratio between the relative peak areas of methylene
backbone of PEI (δ 2.45-3.6 ppm) and succinyl protons (δ 2.25-2.45 ppm) or methyl
protons of acetate (δ 1.85-2.1 ppm). To enable an assignment of the modified PEI peaks,
2D-NMR (HSQC and HMBC) spectra were acquired. (Supplementary information,
Figure 3.10-3.26).

bPEI25k: 1H-NMR δH (400 MHz, D2O, ppm). 2.45–2.85 (bm, PEI)
zPEI: 1H-NMR δH (400 MHz, D2O, ppm). 2.3-2.45 (bs, 4H, –C2H4–COOH), 2.6–3.2
(bm, PEI), 3.3–3.6 (bm, 2H, –CH2–NH–CO-C2H4-).
2D-NMR δH (HMBC, 400 MHz, D2O, ppm). 3°-amide (F1: 174.1 ppm, F2: 2.45 ppm),
2°-amide (F1: 181.4 ppm, F2: 2.45 ppm).
2D-NMR δH (HSQC, 400 MHz, D2O, ppm). –C2H4–COOH (F2: 2.45 ppm, F1:
32.45ppm & 32.55 ppm).
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acPEI: 1H-NMR δH (400 MHz, D2O, ppm). 1.85-2.1 (bs, 3H, NH-CO–CH3), 2.4-3.15
(bm, PEI), 3.3–3.6 (bm, 2H, –CH2–NH–CO–CH3).
2D-NMR δH (HMBC, 400 MHz, D2O, ppm). 2°-amide (F1: 181.3 ppm, F2: 1.86 ppm),
3°- trans amide (F1: 174.1 ppm, F2: 2.01 ppm), 3°- cis amide (F1: 174.1 ppm, F2: 2. 1
ppm)
2D-NMR δH (HSQC, 400 MHz, D2O, ppm). -CO–CH3 (2°-amide, F2: 1.86 ppm, F1:
23.40 ppm), -CO–CH3 (3°- trans amide, F2: 2.01 ppm, F1: 22.03 ppm) & -CO–CH3 (3°cis amide, F2: 2.1 ppm, F1: 20.55 ppm).
FT-IR ν (ATR, cm-1). 1635 (C=O; amide I), 1563 (N-H; amide II). [Common to both
conjugation products]

3.2.3

Ethidium bromide (EtBr) exclusion assay
The formation of polycation-DNA complexes, or polyplexes, was followed by

ethidium bromide displacement assay. Stock solutions of calf-thymus DNA and EtBr
were prepared by dissolving in 10 mM Tris–HCl buffer (pH 7.5) overnight to a final
concentration of 0.24 µg/µL and 0.024 µg/µL, respectively. 12 µg of ctDNA in Tris
buffer (pH 7.5) was incubated with 1.2 µg EtBr at room temperature for 10 min. This
corresponds to a labelling ratio of approximately 1 EtBr per 10 DNA base pairs. After
incubation of the DNA with EtBr, the desired volume and concentration of polymer stock
solutions were added to achieve the desired nitrogen-to-phosphate (N/P) charge ratio. The
resulting polyplexes were incubated for another 30 min at room temperature. After
incubation, the final volume was adjusted to 500 μL using 10 mM Tris buffer before
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measurement by fluorescence spectroscopy. Measurements were performed with samples
in a quartz cuvette. The fluorescence intensity of the polyplex solutions was recorded on
a Thermo Lumina Fluorescence Spectrometer at λex = 520 nm and λem = 610 nm. A
sample containing only pDNA and EtBr was defined as maximum fluorescence (100 %).
The percentage of EtBr displaced upon polyplex formation was calculated by
determining the relative fluorescence (rf%) = [(F-F0)/(FMax-F0)] *100, where F, F0, and
FMax are the emission intensity of the sample, the EtBr alone, and ctDNA/EtBr control,
respectively.

3.2.4

Dextran sulfate displacement assay
The polyplex stability was checked by dextran sulfate displacement. 200 ng

pUC19 samples were complexed with a fixed polymer/DNA weight ratio of 6.0 at a total
volume of 5 µL in 10 mM Tris buffer at pH 7.5. This polymer/DNA weight ratio was
sufficient for a complete complexation of DNA by all polymers used in this study.
Polyplexes were mixed and brought to a total volume of 5µL by addition of 10 mM Tris.
Polyplexes were then incubated at room temperature for 45 mins to ensure complete
DNA complexation. Dextran sulfate (DS) was then added at various weight ratios relative
to the DNA, and the final solution volume was brought up to 12 µL by addition of 10
mM tris buffer. Samples were subsequently incubated for another 30 minutes to allow
plasmid DNA release from the polyplexes. 0.8 w/v % agarose gels were prepared by
dissolving agarose in a 0.2 µm filtered TAE buffer (40 mM Tris base, 20 mM acetic acid,
1 mM EDTA). Before loading onto the agarose gel, 2 µL loading dye was added to each
sample. Samples were electrophoresed for 30 minutes at 100 volts. DNA was visualized
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by post-run staining with ethidium bromide (0.5 µg/mL) and imaged using the BioRad
ChemiDoc MP Imaging System.

3.2.5

Transfection Efficiency
HeLa cells were cultured in DMEM supplemented with 10% FBS according to

ATCC recommendations. Cells were seeded in 24-well plates at 7.5 x 104 cells/well 24 h
prior to transfection. Polyplexes were formed by diluting 20 μL of 0.1 μg/μL pGL3
plasmid DNA solution with 80 μL of phosphate-buffered saline (PBS) in a 1.5 mL
microcentrifuge tube. Polymer solution (100 μL) at various concentrations was added
dropwise to the DNA solution under constant agitation to achieve the desired
polymer/DNA weight ratio. Polyplex particles were allowed to incubate at room
temperature for 30 min. Immediately before transfection, 200 μL polyplex solution was
deposited into 2.8 mL serum-containing medium. Regular growth medium was aspirated
from cells and replaced with 750 μL of polyplex/growth medium solution (0.5 μg
DNA/well). After 4 h, the transfection medium was replaced with a standard growth
medium. Transfection efficiency was then quantified via luciferase expression at 24 h
post initial transfection. A Promega luciferase assay kit was used to measure protein
activity in relative light units (RLU) using a Synergy 2 plate-reader. Results were
normalized to total cell protein using a bicinchoninic acid (BCA) assay from GBiosciences (St. Louis, MO).
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3.2.6

Particle size and zeta potential measurements
Polyplex size and size distribution were measured using dynamic light scattering

(DLS). Polymer/DNA complexes were formed in double distilled water at the optimum
condensing weight ratio for each of the modified and unmodified polymers as determined
by EtBr exclusion assay. Polyplexes were formed as described earlier and following a 30
min incubation at room temperature, the polyplexes were diluted to 2 ug of DNA/mL
using water. The solution was then immediately read using a 90Plus/BI-MAS automatic
particle sizer (Brookhaven Instruments, Holtsville, NY). DLS measurements were
performed prior to zeta (ζ)-potential measurements. To assess polyplex particle charge, ζpotential was measured using a BIC ZetaPALS (Brookhaven Instruments, Holtsville,
NY) at a 15° scattering detector angle. Each measurement was taken in triplicate with 4
runs and 10 cycles acquisition per run. Table 3.1 provides representative particle size
distributions as measured by DLS for each polyplex and reported as mean ± standard
deviation (S.D.).

3.2.7

Circular dichroism spectra
Circular dichroism (CD) spectra of the polyplexes were recorded at room

temperature on a JASCO J-815 CD spectrometer (Jasco International Co. Ltd) using a 1
cm path length cuvette. Each spectrum is the average of three scans over the wavelength
range 220–300 nm with an interval of 1 nm at a scan rate of 100 nm/min.
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3.2.8

Sample preparation for X-ray scattering experiments
For x-ray experiments, fibrous polycation-DNA complexes were formed as

follows. First, concentrated polymer stock solution (1 mg/mL) and stock calf thymus
DNA solutions (2 mg/mL) were prepared in buffer and equilibrated for at least overnight.
The condensing polycations were added to ~200 µg of DNA to achieve the desired N/P
charge ratio where all DNA was shown to be complexed as determined by EtBr exclusion
assay. The resulting fibrous polycation−DNA samples were then incubated at room
temperature for 30 min and centrifuged (14500 g/5 min) to collect the condensate. The
condensate was then moved to a bathing solution of fresh buffer to equilibrate for 1 hour
before X-ray analysis. To mimic transfection-like conditions, two buffers were used
either a 10 mM Tris buffer (pH 7.5) or a 10 mM acetate buffer (pH 4) similar to the low
pH observed in late endosomes. DNA double helix structure is known to be stable over
this pH range. For pH studies, both DNA and polymer were prepared in the same Tris or
acetate buffer and after condensation the condensate were moved to fresh buffer of the
same pH. This maintains the DNA, polycation and polyplex at the same pH throughout
the experiment and therefore labeled as pH 7.5 or pH 4 samples. To look at polyplex
response to acidification a third set of samples were made where the DNA, polycation
and polyplex were formed in 10 mM Tris (pH 7.5) and equilibrated for half an hour.
After equilibration, these samples were then moved to a fresh 10 mM acetate buffer
solution (pH 4) and equilibrated for 1 hr or 1 day before x-ray experiments. These
samples are labeled pH 7.5-4 to indicate the pH change after polyplex formation. For
time course studies, samples were also monitored by X-ray over a month to observe
changes in DNA packaging with time.
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3.2.9

X-ray scattering
Small-angle X-ray scattering experiments (SAXS) were performed using a graded-

multilayer-focused Cu Kα (λ = 1.54 Å) radiation from a Nonius FR-591 rotating anode
fine-focus X-ray generator operating at 45 kV and 20 mA. Samples were sealed in a cell
with a bath of equilibrating buffer solution and mounted in a sample holder at room
temperature. The flight path from the sample to detector was filled with helium gas to
minimize air scatter. The primary beam was collimated by a fine aperture beam tunnel.
Diffraction patterns were recorded with a Platinum 135 CCD detector with phosphor
optimized for Cu Kα radiation, and the images were analyzed with Fit2D and Origin Pro
2019 software. The sample to detector distance for the SAXS was determined using silver
behenate and found to be 22.7 cm. Bragg scattering peaks were used to determine
interaxial DNA-DNA spacings. Bragg spacings are calculated as DBragg = 2π/qBr, where
qBr is the scattering vector q (defined as q = (4π/λ) sinθ, where 2θ is the scattering angle)
and corresponds to the maximum in the scattering. For a hexagonal lattice, the
relationship between the Bragg spacing and the actual interaxial distance between DNA
helices (Dint) is calculated as Dint = (2/√3) DBragg. For samples equilibrated under the same
buffer conditions, D values were reproducible to within ∼0.1 Å. There was no significant

sample degradation due to X-ray exposure or pH buffer conditions. Typical exposure
times were 2 minutes.
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3.3

3.3.1

RESULTS

Synthesis and characterization
To assess the relationship between PEI modifications and the structure of the

resulting DNA complexes, we first synthesized a series of succinylated PEI (zPEI, 240%) and acetylated PEI (acPEI, 10-50%) by modification of 25kDa branched PEI
(bPEI) through reaction with succinic or acetic anhydride. Strategies for the modification
of bPEI were adapted from our previous work (Figure 3.1a) with both zPEI and acPEI
shown to enhance transfection efficiency when compared to unmodified bPEI.88,
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By

varying the feed molar percentages of succinic or acetic anhydride with respect to the
total amine content of PEI, we controlled the percent modification of total amines in the
resulting zPEI and acPEI polymers. Polymer names reflect molar percentage of anhydride
in the feed, so acPEI 10 represents enough acetic anhydride was added to modify 10% of
the total PEI amines. Successful reaction was determined by FT-IR spectroscopy. Upon
modification with either anhydride, two characteristic new peaks at 1635 cm-1 and 1563
cm-1 are observed by FT-IR for both acPEI and zPEI characteristic of the carbonyl stretch
and N−H bend, respectively, of the amide moiety of the modified group after reaction of
the anhydrides with bPEI. The degree of modification was analyzed and quantified by
1

H-NMR from the relative proton peak area ratio between methylene of PEI (2.45-3.6

ppm) and methylene of the succinyl protons (2.3-2.45 ppm) or methyl protons of the
acetyl group (1.85-2.1 ppm). Results are given in supplementary information (Table 3.2).
For most polymers, nearly complete quantitative PEI modification was observed with the
lowest yields obtained for the highest monomer
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Figure 3.1. Synthesis scheme and characterization of zPEI and acPEI. a) Synthesis from
bPEI using succinic anhydride and acetic anhydride, respectively maintaining the same
reaction condition. b) Representative 1H-NMR characterization of unmodified and
modified PEIs. Degree of modification reported as amine/reagent feed ratio. c) & d) 2DHMBC spectra of zPEI 20 and acPEI 40, respectively. Inset (spectra) showing the most
important peaks characteristic of these two polymers. Both spectra confirm the formation
of tertiary amides higher than secondary amides from secondary and primary amines,
respectively.
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feeds of succinyl anhydride (zPEI 30/40). The degree of modification is reported as the %
of total amines modified but, for simplicity, we described the polymers by the PEI
amine/reagent feed ratio. The % modification presented here agrees with the literature
reports from other research groups.97 In Figure 3.1b, we show representative 1H-NMR
spectra of the unmodified bPEI (bottom) compared to zPEI 5 (middle), and acPEI 10
(top).
The bPEI polymer structure has primary, secondary and tertiary amines. It has
been proposed previously that PEI modifications, similar to ours, would primarily occur
at primary amines due to less steric restrictions. To determine where zPEI and acPEI
modifications occurred under our reaction conditions, we performed 2D-NMR (HMBC)
spectroscopy (Figure 3.1c /d). We observe reactions with succinyl, and acetic anhydride
occur more at secondary amines of PEI compared to primary amines. F-1 axis (C-13, yaxis) of the spectra shown in Figure 3.1c, d has two distinct peaks corresponding to
tertiary amides (174.1 ppm) and secondary amides (181.4), respectively. acPEI spectra
differ from zPEI by the chemical environment of -CH3 groups (F-2 axis, 1.86, 1.94, 2.1
ppm) compared to -C2H4- groups (F-2 axis, 2.45 ppm). The methylene protons at 2.45
ppm of zPEI are correlated to 32.45 ppm and 32.55 ppm (Figure 3.1c, inset),
respectively, revealing a similar chemical environment due to carboxyl and amide group
on two opposing sides. This similarity in chemical environment indicates the carboxyl
groups of zPEIs form intramolecular H-bond with the neighboring amines that retain a
negligible deshielding ability on -CH2- near the -COO¯ functional group. The 2D-NMR
data show the relative reaction preference between primary and secondary amines of
bPEI. Accordingly, conjugation starts on secondary amines forming tertiary amides until
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a significant percent modification is achieved. Only at high modification is there
significant reaction of the anhydrides with primary amines to form secondary amides on
both of the modified PEIs in this study. All NMR and FT-IR spectroscopy data are
provided in the supporting information (supplementary information, Figure 3.8-3.26).

3.3.2

Complexation of DNA by bPEI and modified PEIs
A necessary requirement for successful gene delivery is the ability for the

polycation to self-assemble with DNA to form stable polyplex particles. Modification of
PEI is known to alter the ability of the polymer to condense DNA. The ability of bPEI,
acPEI, and zPEI polymers to condense DNA was assessed using ethidium bromide (EtBr)
exclusion assay. Intercalation of EtBr into double stranded DNA results in a significant
increase in the observed fluorescence intensity. Upon complexation of DNA by
polycations, some of the intercalator is displaced resulting in a reduction in the relative
fluorescence intensity. All the polycations, except the highest modified PEIs, display
similar sigmoidal condensation curves due to condensation with the modified PEIs
(Figure 3.2a). bPEI/DNA is fully condensed by polymer/DNA weight ratios of 0.5. zPEI
2-10% and acPEI 10-20% are also able to fully condense calf thymus DNA (ctDNA) to
the same extent as the unmodified bPEI by polymer/DNA weight ratios of 0.5 to 1.0.
acPEI 40, acPEI 50, and zPEI 20 also maintain a sigmodal shape but do not reduce the
relative fluorescence to <5% like lower modified acPEI/zPEI and unmodified bPEI. For
zPEI 20, the EtBr exclusion assay curves shifted to higher polymer/DNA ratios of 3
before plateauing at ~20% normalized fluorescence. For zPEI 30
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Figure 3.2. DNA condensation ability determined with ethidium bromide (EtBr)
exclusion assay. Demonstrated here is the DNA condensation ability of both zPEI and
acPEI, decreasing with increasing % modification. Here, the succinylated PEI has a
relatively lesser DNA condensing power than acetylated PEI. This variability is probably
due to anionic moieties that add up repulsive force between DNA phosphates and
succinyl groups.
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and zPEI 40, we observed a significant change in the shape of the curves suggesting that
zPEI 30 is only partially complexing DNA (normalized fluorescence = 60%) while 40%
modification is unable to condense DNA even at polymer/DNA weight ratios as high as
6. Likely, these differences between zPEI and acPEI are due to the nature of the
modification. Acetylation reduces the net charge of the PEI by replacing a secondary or
primary amine with an acyl group. Acetylation places an acetyl protecting group on
secondary or primary amines of PEI neutralizing the potential positive charge of the
reacted amine. Succinylation of the PEI amines results in grafted succinate groups to the
PEI backbone both potentially neutralizing the charge of the original amine but also
introducing a negatively charged group. Succinylation of PEI clearly has a larger impact
on DNA condensation compared to PEI acetylation.

3.3.3

Dextran sulfate displacement assay
Another well-known bottleneck of polymeric gene delivery is that for gene

transcription to occur the polycation must be able to dissociate from the DNA once inside
the cell. This requires balancing polycation-DNA interactions to create particles stable
enough to reach cells but not too stable to prevent dissociation in cells. One way to tune
these polymer-DNA interactions is through post-polymerization modifications. To
investigate how succinylation and acetylation alter PEI polyplex stabilities, we performed
a dextran sulfate (DS) displacement assay. Here, the sulfated polysaccharide (DS) acts as
a competing polyanion and serves as a mimic of sulfonated extracellular
glycosaminoglycans, such as heparan sulfate, found in vivo that are known to
competitively displace DNA from polyplexes. The relative strength of polymer−DNA
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interactions can be assessed by determining the ability of DS to displace polycations from
DNA at various DS/DNA weight ratios. Here, unmodified and modified PEI polyplexes
were prepared at polymer/DNA ratio of 6 (wt/wt) which was previously determined
sufficient to achieve complete or maximum DNA condensation for all polymers in this
study. These polyplexes were then subsequently incubated with DS at various
concentrations and DNA dissociation was followed by agarose gel electrophoresis.
Results are shown in Figure 3.3. As expected, grafting succinyl or acetyl groups to the
PEI weakens polymer-DNA interactions resulting in a systematic decrease in the amount
of DS required to release DNA from the polyplexes. Unmodified bPEI-DNA (wt/wt 6)
polyplexes requires a DS/DNA weight ratio of 20 for the onset of DNA displacement to
be observed. zPEI 5, 20 and 30 require DS/DNA weight ratios of 15, 2, and 1,
respectively, for significant DNA release to be observed. Acetylation of PEI has a weaker
effect on polyplex stability. acPEI 10, 20, 40 and 50 resulted in DNA displacement
starting at DS/DNA weight ratios of 15, 15, 8, and 8, respectively. These results are
consistent with the weakening of polymer-DNA interactions with increasing amount of
modification of the PEI backbone. The significant differences between zPEI and acPEI at
high modification is again consistent with the acetylation reaction having a weaker effect
on PEI-DNA interactions as compared to the presence of anionic succinyl groups. In
section 3.3.5, these polyplexes are evaluated for their gene transfection efficiency in the
presence of serum proteins. We also examined each complex by DS displacement assay
at the optimum polymer/DNA (wt/wt) ratio based on EtBr exclusion assay
(supplementary information, Figure 3.28) where all polymers were found to fully
condense the DNA.
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Figure 3.3. Dextran sulfate (DS) displacement assay. The numbers above each lane
represent the DS/DNA weight ratio. Polymers were condensed at polymer/DNA weight
ratio 6:1 that shows full DNA condensation achieved by all the modified polymers.
Among the polymers, unmodified PEI retains the most potent DNA binding capability,
reducing with higher modification. Acetylation of PEI retains moderate DNA binding
strength even up to 50%. However, with higher % succinylation displays minimal DNA
binding strength.
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3.3.4

Particle size and ζ-potential measurements
The size and charge of polyplexes are known to be important parameters affecting

transfection efficacy. To compare how bPEI, acPEI and zPEI differ in their ability to
make nanometer-sized polyplex particles, we measured their size by dynamic light
scattering (DLS). Here we focused on polymer/DNA weight ratios sufficient for complete
DNA condensation as determined by EtBr displacement assay. Results are shown in
Table 3.1 with their corresponding polyplex particle diameters (nm) as determined by
DLS. Plasmid DNA size does not affect the physicochemical properties of polyplexes,139
so for these studies, plasmid pUC19 DNA was used to correlate to polyplexes used in
transfection studies. All PEI/DNAs were measured at polymer/DNA weight ratio of 3,
except for zPEI 30 which required wt/wt 6 for full condensation. We hypothesized that
PEI modification would result in larger sized nanoparticles compared to unmodified
bPEI. As shown bPEI/DNA results in nanoparticles exhibiting a mean diameter of 83.8 ±
5 nm. Succinylation in the zPEI series all resulted in larger polyplex particles that
increased in size with higher degrees of polymer modification from zPEI 2 resulting in 98
nm particles to zPEI 20 resulting in 181 nm particles at wt/wt 3. zPEI 30 at wt/wt 6
resulted in even larger (>200 nm) particles. We have reported similar zPEI/DNA particle
sizes in previous studies at similar wt/wt ratios.99 Likely this increase in colloidal size is a
result of having more DNA present in the highly succinylated polyplex particles.
As discussed earlier, polymer chemistry plays a crucial role in the formation of
polyplexes. While succinylation introduces a negative moiety to the PEI polymer,
acetylation increases hydrophobicity. Because of an additional hydrophobic moiety in
PEI structure, polyplexes formed with acPEI possibly complexed with less plasmid DNA.
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Thus, the smaller particle size obtained with acPEI/DNA polyplexes ranging between
87.4-97.1 nm in diameter with increasing % modification. Our results show that
acetylated PEI, even as high as 50% modified, still gives polyplex diameters (87.4-97.1
nm) similar to unmodified bPEI-DNA (83.8 nm).
Next, we determined the resulting zeta potential of the various polyplexes.
Unmodified bPEI/DNA (wt:wt 3:1), resulted in particles with a zeta potential of +21 ±
1.8 mV, consistent with compact polyplex particles with a highly positive surface charge.
As expected, acetylation of PEI amines resulted in a decrease of the polyplex surface
charge which decreased further with increasing percent modification. For example, acPEI
10 decreased the polyplex surface charge to 18.9 mV while acPEI to 50% further reduced
the surface charge to 13.2 mV. The zeta potential of the zPEI series did not significantly
reduce the particle zeta potentials except at the highest % modification studied (30%)
succinylating 2-5% of the PEI amines only reduces the zeta potential to 20 mV.
Increasing succinylation to 20% (zPEI 20) decreased the particle surface charge further to
+14.5 mV. Only at 30% succinylation (zPEI 30, wt:wt 6:1), was a significant change in
the zeta potential observed with particles exhibiting a net negative surface charge (-7.8
mV). These results are somewhat surprising but consistent with our previous studies on
zPEI.99 The negative surface charge upon condensation by zPEI 30 would suggest that
zPEI 30 polyplexes would not be able to have favorable electrostatic interactions with the
negatively charged cell membrane which should be unfavorable for endocytosis.
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Table 3.1. Particle size and ζ-potential
Polymer:
DNA
(wt:wt)

Particle
Diameter
(nm)

ζ-potential
(mV)

PEI
3:1
83.8±5
21±1.8
zPEI 2
3:1
98.3±6
20.1±2.35
zPEI 5
3:1
100.5±7.7
20.02±2.9
zPEI 10
3:1
115.3±5.4
17.04±1.3
zPEI 20
3:1
181.1±5.8
14.54±1.02
zPEI 30
6:1
206.3±19.3
-7.81±0.5
acPEI 10 3:1
87.4±4.1
18.9±0.5
acPEI 20 3:1
86.9±4.5
17.8±1.8
acPEI 40 3:1
87.9±2.7
15.2±1.7
acPEI 50 3:1
94.1±2
13.2±0.8
*Polyplexes formed at the polymer/DNA weight ratio required to obtain full DNA
condensation. The ζ-potential measurement was conducted using the PALS software and
Smoluchowki limit, and the hydrodynamic diameter was determined by applying the
Stokes-Einstein equation from the experimentally determined translational diffusion
coefficient. Data presented as mean±SD (n =3)

3.3.5

Gene transfection efficiency in the presence of serum

Previously reported an improved transfection efficacy for acPEI and zPEI (both in and
out of serum) likely due to decreased charge density of the modified PEIs compared to
bPEI.88, 98-99, 124 Indeed, the enhancement of transgene expression of zPEI in the presence
of serum proteins was shown to meet or exceed expression of bPEI/DNA in the absence
of serum proteins. To further study the effectiveness of these PEI modifications for gene
delivery in the presence of serum, we studied our zPEI and acPEI polymer series for their
effectiveness in transgene expression. Here, HeLa cells were transfected with polyplexes
of the unmodified PEI, zPEI series or acPEI series (Figure 3.4). The unmodified PEI
exhibited the highest levels of transgene expression in the presence of serum at low
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polymer/DNA (wt/wt) ratios of 2 or below. The gene expression of bPEI polyplexes
decreased ~10-fold more at higher wt/wt ratios of 3 or above compared to wt/wt ratio 1.
Minimally succinylated zPEIs (<10%) show the best transgene expression (Figure 3.4a),
consistent with our previous studies reporting an increase with higher polymer/DNA
(wt/wt) ratios by over 100-fold for zPEI 5. Here, maximum gene expression was
observed at polymer/DNA weight ratio 4:1 and 5:1 for zPEI 5 and zPEI 10, respectively.
Compared to unmodified PEI, gene expression by zPEI 5 and zPEI 10 showed 73-fold
and 12-fold higher transgene expression, respectively. Higher succinylation modifications
(>10%) resulted in poor transgene expression for all wt/wt ratios. Prior work with acPEI
showed improvement in transgene expression ability in serum-free conditions.88 In
contrast to serum-free transfections, acetylated PEIs (Figure 3.4b) did not enhance gene
expression in the presence of serum proteins and performed similarly or worse than
unmodified bPEI at all polymer/DNA weight ratios. Improved efficacy shown by acPEI
20 and acPEI 40 at polymer/DNA wt ratios of 6 and 5 that do not agree with general
trend of the acPEI series. Even if we consider these results as not due to random error, the
maximum transgene expression observed was only 1.2- and 0.5-fold higher than bPEI.
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Figure 3.4. In vitro gene transfection efficiency in HeLa cells in the presence of serum.
Luciferase activity in the cell lysates was measured 24 h post-transfection and reported as
relative light units (RLU) normalized by the total protein's mass in the lysate. (n =3, error
bars represent standard deviation)
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3.3.6

Small-Angle X-Ray Scattering
We performed small-angle x-ray scattering (SAXS) experiments to investigate the

nanoscopic structure of unmodified and modified PEI complexes with DNA. Specifically,
we want to assess the relationship between PEI modifications and the resulting DNA
packaging inside the polyplexes. Here, calf thymus DNA were used to form fibrous
polyplex samples as described in the methods. Previous work has shown the DNA
packaging in these fibrous DNA samples is comparable to that achieved in polyplex
nanoparticles.140 In the presence of linear polycations of charge +3 or higher, DNA is
typically self-assembled into a columnar hexagonal arrangement. SAXS experiments
allow for the measurement of the inter-DNA spacings inside the DNA condensate.
Depending on the chemistry of the cation used for condensation, DNA-DNA separations
typically vary from ~27-32 Å with DNA helices separated by water between the DNA
surfaces. Representative normalized scattering intensity profiles from unmodified and
modified PEI-DNA complexes are shown in Figure 3.5. Here, all samples were
condensed in 10 mM Tris (pH 7.5) and allowed to incubate for one hour before SAXS
measurements. bPEI-DNA (0% modified) has a characteristic Bragg peak observed at Q
= 2.533 nm-1 corresponding to a DBragg spacing of 24.7 Å. bPEI-DNA is known to form a
hexagonal lattice so this Bragg spacing corresponds to an interaxial DNA-DNA spacing
(Dint) of 28.6 Å. This is consistent with previous measurements of bPEI-DNA that
showed close-packed DNA.140
We hypothesized that modifications of PEI, either through acetylation or
succinylation, would likely decrease the attractions of the modified PEI relative to
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unmodified PEI resulting in decreased DNA packaging densities (or larger DNA-DNA
spacings). Typically, polycations of net charge +3 or higher are known to spontaneously
condense DNA. 25kDa bPEI has approximately 581 amines and while there is some
debate it is generally agreed that approximately 1/4 to 1/5 of these amines are charged at
near-neutral pH. This corresponds to a net charge of bPEI of approximately +116 to +145
at pH 7. This high net charge of the PEI strongly suggests that even at the highest degrees
of modification used in this study we can expect to be well above the +3 charge threshold
typical for DNA condensation. We next examined the DNA packaging in acetylated PEI
polyplexes with the degree of modification ranging from 0 to 50% (Figure 3.5a, left). A
clear shift of the Bragg reflection to lower Q with increasing percent modification of the
acPEI is observed. As DNA-DNA spacings are inversely proportional to the scatter
vector, Q, diffraction peaks observed at lower Q correspond to larger DNA-DNA
spacings. As Bragg spacings are independent of the array, we focus here on DBragg. The
corresponding DBragg spacings are plotted in Figure 3.5b (left) ranging from 24.7 Å for
0% modified bPEI to 28.8 Å for acPEI 50. Surprisingly, increased succinylation of zPEI
does not behave in this manner.
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Figure 3.5. Representative scattering profiles for zPEI and acPEI-DNA under
'transfection-like' conditions. a) Intensity vs. Q plot obtained from samples prepared in
fresh 10 mM tris buffer (pH 7.5) equilibrated for 1 hour. Scattering vector Q starts to
decrease until 5% succinylation to PEI and then increases again with further % On the
other hand, with increasing acetylation (acPEI 10-50), the Q value decreases. b) The
average DBragg values derived from the maximum Bragg scattering plotted as a function
of PEI modification. The Bragg spacing increases with increasing succinylation (zPEI 25), but the value drops with further modification (zPEI 10-30). As expected with acPEIs,
the Bragg spacing increases with increasing modification. [Here, the condensates were
formed at polymer/DNA weight ratio 0.5, 1.0, 1.0, 1.0, 3.0, 6.0 for bPEI, zPEI 2, zPEI 5,
zPEI 10, zPEI 20 and zPEI 30 while 1.0, 1.5, 2.5 and 3.0 for acPEI 10, acPEI 20, acPEI
40 and acPEI 50 respectively. The results presented as mean±SD (n = 3)]
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Instead, what we see at levels of modification ≤ 5% is a shift of the Bragg peak to lower
Q. As shown in Figure 3.5 b (right), these diffraction peaks correspond to DBragg values
that increase from 24.7 Å at bPEI to a maximum DBragg of 26.7 Å from zPEI 5. With
increasing succinylation, the Bragg peak is observed to shift to higher Q values
corresponding to DBragg ranging from 26.7 to 25.2 Å as the degree of succinylation
changes from 5% to 30% in zPEI-DNA complexes. This tighter DNA packaging in
higher modified zPEI condensates does not correlate to more stable polyplexes, however,
as we already showed that the amount of DS required to release the DNA decreases
steadily with increasing degrees of succinylation, consistent with a weakening of the
polymer-DNA interactions due to the increased amounts of succinyl groups to the PEI
backbone. Using circular dichroism, we also verified that DNA within the polyplexes is
still in B form, consistent with condensation having no effect on the configuration of the
DNA helices (supplementary Figure 3.27). For zPEI 20 and zPEI 30 polyplexes, the
Bragg reflection is significantly broader, suggesting a possible coexistence of two
different phases in this highly succinylated polyplexes. zPEI 40 was not able to condense
DNA, which is consistent with the low transgene expression observed in Figure 3.4.
While the nature of this crossover behavior is not clear, this may suggest that higher
levels of succinylation, while still reducing polymer-DNA interactions, also reduce the
hydration layers between DNA helices allowing for the tighter packaging by zPEIs at
high degrees of modification. Clearly, degree of modification in modified PEIs allows for
the tuning of the polymer−DNA interactions and resulting packing densities in the
polyplex condensates.
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3.3.7

Time course studies by SAXS
Rearrangement within polyplexes is known to occur over time.140 We next wanted

to examine the evolution of our polyplex nanostructure as a function of time after
condensation. Figure 3.6 shows a plot of the measured Bragg reflection as a function of
time for PEI, acPEI and zPEI polyplexes taken at 1 hr, 1 day, 7 days and 1 month after
condensate formation. Here all samples were prepared at 10 mM Tris (pH 7.5). A modest
(~2-3%) rearrangement of the polyplex structure was observed for all the unmodified and
modified PEI polycations over this time period resulting in more tightly condensed
structures over time. Most of the changes in the polyplexes occurred within the first 24
hours after formation. The smallest rearrangements occurred in the highest succinylated
PEIs (zPEI 20/zPEI 30) possibly suggesting these highly succinylated polymers are more
readily able to reach their equilibrium spacings.

3.3.8

Role of pH on DNA packaging in unmodified and modified PEI polyplexes
Altering the PEI through modifications like acetylation and succinylation are

thought to influence gene transfection efficacy by changing the charge density of the PEI
chains thus altering the ability of the modified PEI to condense/release DNA, and
changing other factors including particle size and cytotoxicity.141-142 Although debated,
one of the leading hypotheses of the effectiveness of PEI for gene delivery is based on the
idea of the "proton sponge" effect. This hypothesis is directly related to the large
buffering capacity of PEI. It is suggested that PEI can absorb protons upon acidification
of the endosome, increasing the osmotic pressure and aiding in the rupture and
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Figure 3.6. Interhelical spacings over time. Shown here is the Polymer/DNA internal
packaging assembly of a) zPEI and b) acPEI. Data presented as the average Bragg
spacing for maximum Bragg peaks plotted as a function of time. It requires at least a
week to obtain complete equilibrium with these modified PEI polyplexes.
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subsequent escape of the polyplexes from the endosomes. Release of polyplexes from
endosomes is considered a significant barrier to effective gene delivery.66, 143 Changes in
the protonation of PEI during endosomal acidification has also been suggested to result in
an "overcharging" of the polyplex resulting in a release of PEI and/or looser DNA
packaging helping with the dissociation of the PEI.79, 144-145 While cytoplasmic pH is near
7, endosomes are more acidic. Early endosomes maintain pH near 6.5 and during
maturation become acidified to pH of ~4.5. DNA double helix structures are stable
throughout this pH range, but the charge state of free PEI is known to increase at low pH.
At neutral pH, PEI is thought to have approximately 20% of its amines charged, while at
pH 4 this protonation increases to approximately 60%.48 Since 25kDa PEI consists of
roughly 581 amines per polymer chain, this results in PEI having a net charge of ~ +116
at neutral pH. Lowering the pH further increases the PEI charge due to protonation of
additional amines. At pH 4, this results in a PEI molecule with an approximate net charge
of +349. To examine the effect of pH on the observed DNA packaging in our PEI-based
polyplexes during endosome acidification, we performed SAXS experiments on samples
made at high pH (pH 7.5, Tris buffer) and low pH (pH 4, acetate buffer). Here, both DNA
and PEI stock solutions were prepared in the same pH buffer and subsequently mixed to
form the polyplex. Since low modified zPEI (< 10%) was observed to be most effective
in transfection, we focused on polyplexes made with 10% modified zPEI and acPEI and
compared them to unmodified bPEI. Figure 3.7A shows the representative normalized
SAXS profile curves as a function of the pH at which condensation occurs for bPEI,
acPEI 10 and zPEI 10. In this figure, samples were irradiated approximately one day after
polyplex formation. For unmodified and both modified PEIs, lowering the pH results in a
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shift of the Bragg peak to higher Q or equivalently smaller DNA-DNA spacings. For
example, bPEI-DNA at pH 7.5 has a diffraction peak at Q = 2.53 nm-1 while at pH 4 a
peak at Q = 2.69 nm-1 was observed. This corresponds to Bragg spacings ranging from
24.8 Å to 23.4 Å. acPEI 10 shows a larger decrease in DBragg from 26.5 Å at pH 7.5 to
24.0 Å at pH 4. Similarly, zPEI 10 has a larger decrease in spacings compared to bPEI
with DBragg of 26.3 Å at pH 7 decreasing to 23.3 Å by pH 4. This shift in Bragg spacing
corresponds to a ~5.6% change in spacing for bPEI compared to a ~9.4 to 11.4% change
in the 10% modified PEIs when condensed at pH 4 compared to pH 7.5. Under most
transfection conditions, polyplexes would be formed at near neutral pH and only be
acidified after the formation of the complex. Therefore, we also created a third set of
fibrous samples, pH 7.5-4, which were formed and equilibrated for 1 h in Tris buffer (pH
7.5), then transferred to acetate buffer (pH 4) and equilibrated again for 1 h before SAXS
measurements. Blue curves (pH 7.5-4.0) in Figure 3.7A show SAXS scattering profiles
for these samples. In all three systems, we see a shift to higher Q upon acidification that
is intermediate compared to polyplexes condensed at pH 7.5 (black curves) and pH 4.0
(red curves). This is most likely due to bound PEIs in the polyplexes having different
pKas compared to unbound PEI free in solution. This different pKas result in preformed
polyplexes being less sensitive to changes in pH compared to complexes formed at
different pHs.
Lastly, we also did a time course study for these different pH samples to check for
rearrangements over time inside the polyplexes. Figure 3.7B shows a plot of DBragg as a
function of time for bPEI, acPEI 10 and zPEI 10 for all three pH conditions (pH 4, 7.5
and
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Figure 3.7. Modified PEI/DNA packaging density changes with pH. a) I vs. Q plotted as
a function of scattering vector Q (data obtained after equilibrating the condensate for 1day in designated pH). b) The pH effect on DNA interhelical spacing over time. [pH 7.5
(black): pellets formed in pH 7.5 buffer and transferred to fresh buffer to equilibrate for
1- hour & 24-hours, respectively. pH 7.5-4.0 (blue): pellets were formed in pH 7.5 buffer
and then transferred to equilibrate in pH 4.0 acetate buffer (1-hour & 24-hours). pH 4.0
(red): pellets were formed with polymer & DNA solutions (pH 4.0 acetate buffer as
solvent) and transferred the pellets to fresh pH 4.0 buffer.]
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7.5-4). As polyplexes are not likely to stay complexed in vivo for long times, we focused
on changes in DNA packaging within 24 hours. For all three polyplex systems, the
observed DBragg decreased slightly (~2%) at 24 hours compared to 1 hour incubation. For
pH 7.5-4 samples, additional incubation at pH 4 resulted in zPEI 10/DNA having fairly
large structural rearrangements resulting in a DBragg closer to that observed for zPEI 10
polyplexes condensed at pH 4. pH 7.5-4 samples for bPEI and acPEI 10 polyplexes
however still have DBragg peaks closer to those observed for polyplexes formed at pH 7.5.
All the Q and Dbragg values for these plots are tabulated in supplementary Table 3.4. The
larger structural rearrangements for zPEI 10 polyplexes may suggest that the pKas of
bound zPEI are closer in value to the pKas of unbound zPEI.
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3.4

DISCUSSION
A nonviral polymer gene therapy carrier faces several intra- and extracellular

barriers before successful gene transfection.72,

146-147

First, the polyplex must travel to

targeted cell while avoiding degradation of its payload by nucleases or clearance by the
reticuloendothelial system. Upon arriving at the target cell, the polyplexes must interact
with the negatively charged cell walls and be taken up into the cell through processes like
endocytosis. For polymer gene delivery, these polyplex particles must then escape the
endosome while also passing through the complex cytoskeletal network in the cell
cytoplasm on their way to the nucleus. Then ultimately the polyplex must pass the
nuclear envelope while also releasing its DNA for successful gene transcription of its
payload.148-151 The cationic polymer, polyethylenimine (PEI) has proven to be one of the
most successful polymers for gene transfection and is often considered a benchmark for
polymeric gene delivery. The high charge density of PEI, however, also means it is
cytotoxic and therefore may not be sufficiently biocompatible for clinical applications.152
To mediate this cytotoxicity, as well as to optimize gene delivery, a common strategy has
been to modify PEI through reaction with the primary and secondary amines on the PEI
backbone. Grafting different functional groups to PEI mediates polymer-DNA
interactions, altering the binding and release of DNA by the modified PEIs, and often
reduces the cytotoxicity of the polymer.
In prior work with acetylated and succinylated PEI, it was shown that
modifications result in weakened binding to DNA, and the competitive release of DNA
from polyplexes increases with increasing modification. In these newly synthesized zPEI
and acPEI series, we again see the same behavior. By ethidium bromide exclusion assay
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(Figure 3.2), we show that more polymer is needed to fully condense DNA with
increasing levels of modification by both succinylation and acetylation. Using a dextran
sulfate displacement assay (Figure 3.3), we also see acetylation and succcinylation
weaken polymer-DNA interactions resulting in more DNA released by competitive
displacement by dextran sulfate. Although secondary amines are more nucleophilic than
primary amines,153 it is generally assumed that PEI modification occurs mostly at primary
amines due to steric hinderance of the secondary amines in the PEI chain.88, 97 Using 2DNMR, we experimentally tested this (Figure 3.2) and found that both acetylation and
succinylation actually occur preferentially at secondary amines, especially at lower levels
(≤10%) of modification. At higher levels of modification, we see an increase in
modification of primary amines yet secondary amines are still modified more. The
colloidal and charge properties of the resulting polyplex nanoparticles were also
investigated by DLS and zeta potential measurement (Table 3.1). Acetylation at all levels
was found to result in polyplex nanoparticles nearly identical in size to bPEI/DNA.
Acetylation also decreases the particle surface charge slightly by 10% modification, and
zeta potential decreased further at higher levels of modification. zPEI polyplexes in
general were observed to be larger (~2x) than both bPEI/DNA and acPEI/DNA. This may
reflect more aggregation is occurring in the zPEI formation. Surprisingly, the
incorporation of the negatively charged succinate groups for zPEI did not affect zeta
potential very much up to ~20% modification. The decrease in zeta potential in zPEI is
quite similar to acPEI up until 30% modification where zPEI 30/DNA reversed sign and
negative particle surface charge was observed. This correlates well with the very poor
transfection efficacy of zPEI 30/DNA at all weight-to-weight ratios (Figure 3.4).
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In prior work, it was reported from our group and others that acPEI and zPEI
result in enhanced transfection in both the absence and presence of serum proteins.88, 99
Forrest, et. al reported a 21-fold increase in acPEI transfection in serum, while we
recently showed even minimally succinylated zPEIs as low as 2% can result in 260- to
480-fold enhancement in the transgene expression when compared to unmodified PEI.
Although the mechanism is still unclear, both modifications suggest that altering the
protonation properties of PEI enhances gene delivery activity. These new series of acPEI
and zPEI were also tested for their transfection efficacy in HeLa cells in the presence of
serum proteins for direct comparison to our biophysical characterizations and the results
are given in Figure 3.4. In agreement with our most recent manuscript, succinylation at
modifications ≤ 10% showed a large enhancement in transgene expression compared to
bPEI/DNA in the presence of serum proteins. With increasing polymer/DNA (wt/wt)
ratio, bPEI/DNA gene expression decreased. In contrast, zPEI 5 and zPEI 10 show
increasing transgene expression at higher polymer loading with zPEI 5 being 318-472x
higher transgene expression at wt/wt 4 and 5 compared to bPEI at the same loading. In
contrast, acPEI did not show an enhancement for transgene expression in the presence of
serum in these experiments. acPEI/DNA performed worse in nearly all weight:weight
ratios when compared to bPEI/DNA. The exact mechanism for this enhancement of
zPEI/DNA in the presence of serum is still not fully understood. However, a similar
enhancement of transfection in serum was reported using a biodegradable PEI-mimetic
polymer, similar to linear PEI, where the ratio of primary, secondary and tertiary amines
was controlled.154 Similar to zPEI, these PEI-mimetic polymers showed only slightly
higher efficacy without serum that increased when serum proteins were present. In their
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polymers, a ratio of 1:4:1 for primary:secondary:tertiary amines was found to be optimal
for gene transfection. In contrast, our zPEIs, based on branched PEI, are primarily
modified at their secondary amines most likely decreasing the ratios of secondary amines
below the optimal ratios for the PEI-mimetic polymers.
We next used X-ray experiments to examine the nanostructured ordering of the
DNA helices condensed in the polyplexes. As discussed in the introduction, cations of net
charge +3 or higher, can self-assemble with DNA to form highly compacted structures.
Upon condensing, DNA is typically ordered into hexagonal arrays where ~5-15 Å water
layer separates the DNA helices.126, 155 This water layer represents a balance between the
attractive and repulsive forces within the condensed cation/DNA phase. In previous work,
osmotic pressure combined with small-angle X-ray scattering experiments to
experimentally determine the attractive and repulsive contributions to the free energy for
a variety of linear polycation-DNA systems.127-129,

156

Using small arginine peptides, it

was reported that the incorporation of uncharged amino acids, such as alanine or serine,
and the incorporation of anionic amino acids, such as glutamic acid or phosphorylated
serine, had the effect of increasing the repulsive interactions while simultaneously, but to
a lower extent, decreasing the attractive interactions.128 The net result of these effects was
to alter peptide-DNA interactions leading to larger DNA-DNA spacings in the modified
peptide/DNA systems. In particular, the incorporation of a negative moiety, significantly
increased repulsions, and the resulting DNA-DNA spacings were much larger compared
to the incorporation of an uncharged amino acid. Based on these results, we hypothesized
that both acPEI and zPEI would result in lower DNA packaging densities in comparison
to bPEI. Higher degrees of modifications would be expected to further decrease
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attractions and increase repulsion leading to more loosely structured polyplexes with
zPEI/DNA having the largest DNA-DNA spacings. We observed similar trends with a
succinylated PAMAM dendrimer system where only primary amines of the dendrimer
were succinylated.157-158 Succinylated PAMAMs were still able to condense DNA up to
40% modification. The succinylated PAMAMs showed more modification resulted in
decreased DNA packaging and even a phase transition from a columnar hexagonal to a
columnar square lattice at the highest modifications. Tuning DNA-dendrimer interactions
in this way was an effective tool to tune the resulting DNA packaging resulting in DNADNA spacings ranging from 28 Å for unmodified PAMAM to 40 Å for 40% succinylated
PAMAM. PAMAM is also similar to bPEI as being a heavily branched polycation that
would not likely coordinate in the grooves of the DNA helix in a manner comparable to
linear polycations. Here, we see different behavior. Acetylation does show a monotonic
increase in the DNA-DNA spacings with increasing levels of modification (Figure 3.5).
The change in Bragg spacings, however, was smaller varying from 24.8 Å to 28.8 Å by
50% acetylation. These results are similar to what we observed in the short arginine
peptides where incorporating a non-charged amino acid had relatively small effects on
the attractive and repulsive forces within the condensate. The most significant difference
was with zPEI (Figure 3.5 b). At low levels of succinylation (<10%) we do see DNADNA spacings increase. 5% succinylation has a similar effect as 10-20% acetylation in
the resulting DNA packaging inside the polyplexes. Surprisingly, though at still higher
levels of succinylation, the SAXS measured DNA-DNA spacings monotonically decrease
for modifications of 10 to 30%. Despite this apparent tightening of the DNA-DNA
spacing, we show (Figure 3.2/3.3) that high modification of zPEI greatly reduces
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polymer-DNA interactions creating polyplexes that are easier to dissociate. By 40%
modification, zPEI was no longer able to condense DNA. The decrease in DNA spacings
for moderate succinylation would suggest that zPEI is decreasing the water layers
between DNA helices. Another possibility is if DNA changes form upon condensation to
form a small diameter helix (such as Z-form DNA). Generally double stranded DNA is in
B-form resulting in a double helix with a diameter of 2 nm. Even after condensation,
most experiments have shown DNA maintains B-form. To verify that zPEI/DNA
maintains B-form DNA, we performed circular dichroism (CD) experiments
(supplementary information, Figure 3.27). The spectrum for zPEI/DNA is comparable to
free DNA strongly suggesting zPEI is not altering the DNA upon binding. Using time
course studies (Figure 3.6), we also show that the resulting polyplexes are able to
reorganize themselves over the course of days to create more tightly packaged DNA
assemblies were relatively small (~1.5-2.5%) over the course of 30 days and most of the
rearrangements occurred in the first 24 hours. This suggest polyplexes like PEI-DNA get
trapped in nonequilibrium states due to the strong binding of the polycation but can get to
more equilibrium state over time. Interestingly, zPEI 30 showed less rearrangement
(~0.5%) potentially suggesting the high level of succinylation decreased polymer-DNA
interactions sufficiently to more readily reach equilibrium. Acetylation, even at 50%
modification, did not show this effect.
Lastly, we examined the effect of pH on the unmodified bPEI and modified PEI
polyplex DNA packaging. During transfection, polyplexes would be expected to
experience different pH depending on their location. Typically, polyplexes are first
formulated in water or in buffers such as HEPES, PBS or Tris with pH near 7. If injected
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into the body, polyplexes would see similar pH in blood (~7.35-7.45). Once endocytosed
into cells, however, the polyplexes would experience lower pH ranging from ~6.5 in
early endosomes to pH 5.5 in late endosomes. When maturing into lysosomes, pH is even
lower at 4.5. To mimic the pH range experienced in vivo, we therefore looked at PEI
polyplexes packaging in pH 7.5 buffer (Tris) and in pH 4.0 buffer (acetate). DNA
packaging in the polyplexes was measured by X-ray diffraction (Figure 3.7). bPEI is
known to have only about 20% of its amines charged at neutral pH but this charge state
can increase to approximately 60% by pH 4. As shown in Figure 3.7, we show that the
pH at which condensation occurs can have a large effect on the resulting internal
packaging of the DNA. For all three polymer systems (bPEI, zPEI and acPEI),
condensing at low pH resulted in significantly higher DNA packaging densities in the
resulting polyplex as compared to condensation at pH 7.5. Previous studies have shown
that using acidic culture medium enhanced polymeric transfection efficiency but acidic
transfection medium reduce efficacy.142 To mimic the effect of acidification of
polyplexes in late endosomes and lysosomes, we also looked at DNA packaging that was
preformed at near neutral pH (Tris pH 7.5), equilibrated for 1 hour, and then transferred
the polyplex to acidic pH 4 buffer. These samples are labeled as pH 7.5-4 in Figure 3.7.
Due to the presence of uncharged amines in PEI, a hypothesis for the relative high
transfection with PEI is known as the "proton sponge effect".144, 159 This hypothesis is
based on the pH-buffering capacity of PEI. It is argued that having PEI present in
endosomes during acidification will result in increased osmotic pressure as the PEI
increases in charge and more anions are required to neutralize the PEI charge.160 This
increased osmotic pressure is argued then to help rupture endosomes allowing more
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PEI/DNA polyplexes to be released in the cytoplasm. Commonly, it is also proposed that
the PEI in polyplexes overcharges in an acidic effect causing enhanced repulsions and
leading to the polyplex structure either swelling or loosening in the endosome.79, 144-145
This hypothesis is disputed, however, with recent experimental and theoretical data
seemingly both supporting79,

149, 161

and not supporting it.150,

162-163

Others have also

argued that PEI, either free or bound in polyplexes, may interact with the endosome
membrane in some manner that results in endosomal rupture.162,

164-166

By SAXS

experiments, we find that once formed, unmodified and modified PEI is able to
reorganize its structure to tighten, not loosen, DNA packaging. The pH 7.5-4 samples
achieved intermediate DNA packaging when compared to samples condensed directly at
pH 7.5 or pH 4. This likely is due to the pKas of the complexed PEI, acPEI and zPEIs
being different than the unbound polymers resulting in the PEIs not achieving the same
charge state inside the polyplex that they achieve in free solution. Interestingly, the
succinylated zPEI showed the largest sensitivity to changing the pH which may aid in its
transfection efficiency. The tightening of the DNA-PEI complex due to acidification is in
good agreement with recent all-atom molecular dynamic simulation results by Antila, et
al.167 Their simulations suggest upon acidification PEI chains do not swell or fall apart
due to overcharging but may lead to more PEI chains being freed from the polyplex and
that these chains may contribute to release from endosomes by other mechanisms.

3.5

CONCLUSION
In summary, we have investigated the effect of acetylation and succinylation of

branched PEI on the resulting biophysical properties, transfection efficiency, and
nanoscopic internal structure of the resulting condensates. Through 2D-NMR studies, we
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show that both modifications are preferential to secondary amines on the bPEI with
primary PEI amines being modified only at higher percent modifications. As expected,
higher degrees of modification reduce polymer−DNA interactions resulting in less stable
polyplexes. Transfections in the presence of serum proteins show enhancement by the
succinylated PEIs (zPEI), while acetylated PEI (acPEI) performed the same or worse than
unmodified bPEI/DNA. Inter-DNA spacings were examined by SAXS experiments as a
function of degree of modification. Acetylation resulted in a monotonic increase in Bragg
spacings inside the acPEI polyplexes, while zPEI showed a surprising crossover behavior
where DNA-DNA spacings increase at low modification but then decreased at higher
modification. We also examined the pH dependence of the PEI and modified PEI
polyplexes at pHs relevant to transfection conditions. We show that changing the pH at
which the polyplex is condensed alters the resulting DNA packaging in all the
polyplexes. Lowering pH, resulting in a more highly charged PEI polymer, results in
significantly tighter DNA packaging. Lastly, we took preformed polyplexes condensed at
near neutral pH and then exposed them to low pH buffer (pH 4), similar to pH a polyplex
might encounter in a lysosome. The polyplexes become more tightly packaged upon
acidification with a DNA packaging intermediate than observed for polyplexes directly
condensed at neutral or low pH. The succinylated PEIs showed the largest response to
changes in the solution pH with significant restructuring of their internal structure upon
exposure to low pH buffer. These studies highlight how tuning polymer-DNA
interactions through PEI modification and pH is a valuable tool to engineer optimized
PEI based gene delivery agents.
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3.6
3.6.1

Supplementary Information
Characterization of polymers with FT-IR (ATR)
All the zPEIs and acPEIs were characterized for functional groups with an iS50

FT-IR equipped with a diamond ATR (at 4000-400 cm-1) on solid polymer stocks
through OMNIC software (ThermoFisher Scientific; Waltham, MA). FT-IR spectra are
plotted in Figure 3.8 & 3.9 with the stretch and bend peaks for ethylene, amine, amide,
and carboxyl functional groups identified. Polymer modification success was determined
by inspecting the spectrum near the fingerprint region. Peaks at 1599 and 1455 cm-1
indicates -N-H (amine) and -C-H (ethyl) bend peak of bPEI while at 1635 cm-1 and 1565
cm-1 were assigned for carbonyl stretch and N-H bend (amide, CO-NH), respectively.
Within the spectrum, the C-O-H bending mode for carboxylic acid was identified at 1386
cm-1 while

Figure 3.8. FT-IR of zPEIs with modification regions labelled
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Figure 3.9. FT-IR of acPEIs with modification regions labelled
C-O of carboxylic acid and C-C stretch at 1293 cm-1 further proves the succinylation and
acetylation reactions to be successful.

3.6.2

Characterization of polymers with NMR (H-NMR, HMBC, HSQC)
Both 1D and 2D-NMR characterization was conducted on an Avance Neo

spectrometer (400 MHz) instrument on approximately 6.5 mg polymer dissolved in 0.65
ml D2O, and data were analyzed with topspin 4.0.3 data analysis software. From the 1HNMR spectrum, three chemical shift regions supporting the Branched PEI methylene
protons base peaks were identified at δ2.6-3.6 ppm while the peak region δ2.3-2.4 ppm
was for succinyl methylene protons and 1.8-2.1 ppm for three protons of the methyl
group conjugation with acetylation (Figure 3.10-3.19). As the mole ratio of succinic
anhydride or acetic anhydride to branched PEI increased to get higher % modification,
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the peak area also increased proportionally. The modification region in the 1D-NMR
spectrum for acetylation has more than two peaks which made the characterization
challenging, so 2D-NMR with HMBC was performed. The coordinates at F1: 181.3 ppm,
F2: 1.78 ppm was assigned for 2°-amides, while 3°- amide show isomerism at F1: 174.1
ppm, F2: 1.86 ppm for trans amide, while F1: 174.1 ppm, F2: 2.0 ppm for cis amide
(Figure 3.20). The % degree of modification was calculated using the integral areas of
succinyl peak divided by bPEI amine base peaks. Thus, nearly a quantified modification
series of 8, 21, 29 and 35% zPEIs and 11, 22, 41 and 53% acPEIs were characterized.
The percent modification is tabulated in Table 3.2.
The chemical structure in Figure 3.20 shows the most important peak
assignments for succinylation. HMBC spectra of zPEI 20 shows the long range 1H-13C
correlation which are three or two bonds away. So, proton (b at 2.45 ppm) is correlated to
the carbonyl carbon (C-4, at 181.4 ppm) of the 2°-amide group by three bonds. For the
same reason, proton Hb show strong correlation to C-5 (at 174.1 ppm) of the 3°-amide
carbonyl carbon. Protons Ha and Hb also correlated between each other via two bonds at
32.45 (C-3) and 32.55 ppm (C-2) respectively along the F-1 axis (vertical axis). Inset
correlation peak showing two carbons at 32.5 ppm (F1-axis) as a proof that the proton
peaks between amide and carboxyl groups are merged along F-2 axis (Figure 3.20,
inset). This shows a similar chemical environment imparting on two adjacent methylene
protons (-CH2-CH2-) due to amide and carboxyl groups respectively. Both Hd and He are
strongly correlated to amide carbonyl (C-4 & C-5) is a proof of a successful conjugation
to both primary and secondary amines (further proved with HMBC spectra of acPEIs). Hd
and He also forms two bond correlation peaks with PEI base carbons at around 50-60
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ppm (F1 horizontal axis). Unfortunately, peaks for the Hc could not be resolved from this
HMBC spectra. HSQC spectra of zPEI 5 and zPEI 20 further supports the successful
succinyl conjugation by showing 1-bond 1H-13C correlation between F1: 32.45/32.55
ppm and F2: 2.45 ppm (Figure 3.21 & Figure 3.22). Because of single bond 1H-13C
correlation, we do not see any contour plot arising at downfield region (F1- axis, at 170185 ppm) with C-4 or C-5 carbons.
Inset chemical structure in Figure 3.23 shows the most important peak
assignments for acPEI 40. HMBC spectra shows the long range 1H-13C correlation which
are three or two bonds away. Here, the peaks arising with the modification must have two
bond 1H-13C correlation. So, protons ‘a’ at 1.86 ppm are correlated to the carbonyl carbon
C-2, at 181.4 ppm of the 2°-amide group by two bonds. For the same reason, proton He &
He* show strong correlation to C-3 (at 174.1 ppm) of the 3°-amide carbon. Unlike zPEI,
these protons do not show any correlation peak around the modification region (up
field~30.0-35.0 ppm along F-1 horizontal axis), proving the differences in chemical
environment originating due to succinyl and acetyl functionality. HSQC spectra further
supports the difference in chemical environment due to the attachment of three different
types of -CH3 groups (Figure 3.24). Both He and He* show different 1H-13C single bond
correlation peaks depicting a possible presence of isomerism which could not be
identified by current experiment. HMBC experiment was further conducted at very low
pH (~2) to see whether the conjugation peaks shift to up/downfield. The reason was to
identify any possibility of carboxyl group in the acPEIs. This experiment shows the
position of the correlation peaks at the modification region, although merged, of acetyl
group remains unchanged (Figure 3.25). Because of the high electron withdrawal effect
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of Cl-, the PEI base peaks shifts to 2.9-3.8 ppm. Unfortunately, the presence of carboxylic
acid, if present, could not be explicitly distinguished from these spectrums because of
their similar resonance to amide carbonyl carbons. However, these spectrums confirm
that the secondary amines of the branched PEI start to conjugate first followed by
primary amines. The argument is supported by the HMBC spectra of acPEI 20, where we
see the integral area of the peak at 1.86 ppm is almost negligible (correlated to F1: 181.4
ppm) (Figure 3.26). With an increasing degree of modification shown in acPEI 40
(Figure 3.23), the integral area of this peak increases linearly.

Table 3.2 Composition of modified PEIsa
b
Polymer ID
Reagent/amine*100%,
Modification degree, %
feed
zPEI 2
2
2
zPEI 5
5
4.8
zPEI 10
10
8
zPEI 20
20
21
zPEI 30
30
29
zPEI 40
40
35
acPEI 10
10
11.2
acPEI 20
20
22
acPEI 40
40
41
acPEI 50
50
53
a
The nomenclature of the polymers is expressed as follows: xPEI-y, where x represents
the reagent by which PEI was modified (x = z or ac, where z = succinic anhydride and ac
= acetic anhydride, respectively) and y represents the modification degree of amins used
as feed ratio. Throughout the manuscript the feed ratio was used for consistency.
b

Modification degree of amines measured by 1H-NMR
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Figure 3.10. 1H-NMR of zPEI 2

Figure 3.11. 1H-NMR of zPEI 5
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Figure 3.12. 1H-NMR of zPEI 10

Figure 3.13. 1H-NMR of zPEI 20

106

Figure 3.14. 1H-NMR of zPEI 30

Figure 3.15. 1H -NMR of zPEI 40

107

Figure 3.16. 1H-NMR of acPEI 10

Figure 3.17. 1H-NMR of acPEI 20
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Figure 3.18. 1H-NMR of acPEI 40

Figure 3.19. 1H-NMR of acPEI 50
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Figure 3.20. HMBC-NMR (2D) of zPEI 20

Figure 3.21. HSQC-NMR of zPEI 20
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Figure 3.22. HSQC-NMR of zPEI 5

Figure 3.23. HMBC-NMR (2D) of acPEI 40
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Figure 3.24. HSQC-NMR (2D) of acPEI 40

Figure 3.25. HMBC-NMR (2D) of acPEI 40 at pH 2.0
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Figure 3.26. HMBC-NMR (2D) of acPEI 20 as reference, showing the conjugation
reaction preference for secondary amines of branched PEI followed by primary amine
conjugation. With higher modification, the integral area of the peak at F2 1.86 ppm & F1
181.4 ppm coordinates get higher as shown in Figure 3.23.

3.6.3

Circular Dichroism (CD)
Samples of calf thymus DNA polyplexes with acPEI 40 and zPEI 30 were

prepared at wt/wt ratio 3.0 and 6.0, respectively, and placed in a quartz cuvette with an
optical path of 1 cm. The CD spectra of these polyplexes were compared to CD spectra of
uncondensed DNA. Samples were analyzed with a Jasco J-815 spectropolarimeter. CD
spectra were collected from 220 to 300 nm at a scanning speed of 100 nm/min. A total of
3 scans were collected and averaged for each sample. Apart from hypsochromic shift
with acPEI, both polymers showed similar spectra typical to that of ctDNA, most
frequently observed for B-conformation, as a proof of no DNA transition occurs.
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Figure 3.27. Circular Dichroism spectra of calf thymus DNA. The spectra obtained with
JASCO (J-815) CD spectrometer (Japan) and analyzed with JASCO spectra manager
software. The spectrum obtained at room temperature for 0.1X PBS buffer solution of
ctDNA complexed with acPEI 40 and zPEI 30 at a polymer/DNA weight ratio obtained
from EtBr exclusion assay.

3.6.4

Electrophoretic mobility shift assay at DNA condensation weight ratio
Agarose gel electrophoresis was used to assess each modified polymers' relative

polyplex stability at specific polymers' condensation weight ratio determined by EtBr
exclusion assay (Figure 3.3b). Polymers were condensed at polymer/DNA weight ratio
0.5, 1, 1, 1, 3, 6 by the PEI, zPEI 2, zPEI 5, zPEI 10, zPEI 20, and zPEI 30 while 1, 1.5,
3.0, and 3.0 weight ratio for acPEI 10, 20, 40 and 50 respectively. At this threshold
condensation weight ratio, polymers can hardly withstand competitive counterion.
Because of a negative COO- moiety added to bPEI, polyplexes formed with zPEI
maintain weak electrostatic interaction between polymer and DNA. Hence, the zPEI
polymers release DNA from condensed polyplex by a DS/DNA weight ratio of 0.5-1.0.
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In contrast, acPEIs show relatively strong polyplex packaging. Thus, DNA release occurs
at DS/DNA weight ratio between 1.0-2.0.

Figure 3.28. Dextran sulfate (DS) displacement assay at polymer/DNA condensation
weight ratio obtained from EtBr exclusion assay.
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Table 3.3. DBragg changes over time and polymer modification
Polymer
DBragg (1hr)
DBragg (30 day) Delta D (D 1hr
Å
- D 30) Å
Å

% Change
[delta D / D
Bragg (1hr)]

bPEI

24.71

24.28

0.43

1.74

zPEI 2

25.1

24.75

0.35

1.4

zPEI 5

26.7

26.06

0.64

2.4

zPEI 10

26.21

25.54

0.67

2.56

zPEI 20

25.636

25.25

0.39

1.52

zPEI 30

25.19

25.06

0.13

0.52

acPEI 10

26.525

26.05

0.48

1.8

acPEI 20

27.01

26.5

0.51

1.9

acPEI 40

27.68

27.4

0.28

1.01

acPEI 50

28.83

28.23

0.6

2.08

3.6.5

pH effects on the observed SAXS Bragg peaks and calculated DBragg values
Polyplexes of bPEI, acPEI 10 and zPEI 10 were formed at different pHs and

measured by SAXS to evaluate changes in the internal structure of the resulting
polyplexes. Samples were either formed in 10 mM Tris (pH 7.5) or 10 mM acetate buffer
(pH 4) or were preformed for 1 hour in Tris then transferred to the acetate buffer for
equilibration (pH 7.5-4). All complexes resulted in a single diffraction peak being
observed and the corresponding Q and DBragg values are tabulated in Table 3.4.
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Table 3.4. Role of pH in interhelical spacings within condensed DNA. Here, sample ID 1
and 2 represents as mean±0.2 (n =2) while sample ID 3 (n =1)
Sample ID
pH
**After 1-hour
**After 24-hour equilibration
equilibration
Q(nm-1)
Q(nm-1)
DBragg
DBragg
(Å)
(Å)
PEI-1
7.5
24.8
2.57
24.5
2.53
PEI-2
7.5-4.0
24.8
2.62
24.0
2.53
PEI-3
4.0
23.4
2.71
23.2
2.69
zPEI 10-1
7.5
26.3
2.44
25.7
2.39
zPEI 10-2
7.5-4.0
25.7
2.61
24.1
2.44
zPEI 10-3
4.0
23.3
2.71
23.2
2.7
acPEI 10-1
7.5
26.5
2.38
26.3
2.36
acPEI 10-2
7.5-4.0
26.1
2.48
25.3
2.4
acPEI 10-3
4.0
24.0
2.65
23.7
2.61
*pH 7.4: Pellets were transferred to the same fresh buffer, pH 7.4-4.0: Pellets were
transferred from pH 7.4 to 4.0 and pH 4.0: When polymer solution was prepared with 10
mM acetate buffer as a solvent and then condensed pellets formed with subsequent
transfer of these pellet to fresh pH 4.0 buffer.
**Time for equilibration after pellets are transferred to respective buffer solutions to
attain stable packaging.
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CHAPTER 4. ROLE OF VARYING PROTEIN CONCENTRATION AND PRETREATED POLYPLEXES ON SUCCINYLATED POLYETHYLENIMINE
MEDIATED GENE TRANSFECTION
Preface: This work was performed in collaboration with the group of Dr. Daniel Pack of
the Departments of Chemical & Materials Engineering and Pharmaceutical Sciences at
the University of Kentucky. All polymer synthesis, characterization, and gene
transfections were completed by the author. The fluorescence imaging experiments were
performed by Dr. Logan Warriner in the laboratory of Dr. Daniel Pack.

4.1

Introduction
Polymer-based therapeutics holds the promise to treat almost any disease through

the emerging fields of gene silencing, protein expression, drug and RNA delivery, or
genetic modification. Over the past few decades, intense efforts have been made to
optimize and understand the mechanism of nanoparticle (NP)-based formulations for
effective payload delivery. Complexes involving polymers for therapeutics, for example
polycation-DNA complexes (or polyplexes) used for nonviral gene delivery, typically
result in the formation of nanoparticles. In vivo, these nanoparticles come into contact
with high concentrations of serum proteins that can adsorb onto the nanoparticle surface
to form a protein layer called a protein corona.168 This protein corona often determines
how the nanoparticle then interacts with the surrounding biological materials.168 The
protein-nanoparticle interactions, in turn, determine the particles' size, shape, aggregation
state, pharmacokinetics, and therapeutic efficacy in vivo, that can vary with patient
physiology to form the so-called personalized protein corona.168-170 Proteins are also not
the only binding agent found on the surface of the corona with cholesterol and
triglycerides known to also potentially adsorb on the surface to form a corona.169, 171-172
For example, apolipoproteins, cholesterol, and triglycerides were found to show a high

affinity to bind effectively to the surface of the carboxylated polystyrene nanoparticles
.171 In a study with gold nanoparticles, major serum proteins such as immunoglobulin G,
fibrinogen, apolipoprotein A and albumin exhibited aggregation at low concentration but
show colloidal stability at higher concentrations due to complete corona formation.173
The difference in corona type significantly impacts nanoparticle-cell membrane
interaction, endosomal uptake, intracellular trafficking, and subsequent release
pathways.174-176 Literature reports that specific proteins in the original corona were
retained on the surface of polymeric nanoparticles until they accumulated in lysosomes
and degraded.177 One significant finding of this study was that the serum proteins could
exhibit different intracellular processing when carried inside cells as part of the
nanoparticle corona, as compared to unbound proteins in the extracellular medium.177
Another study suggests that the protein coronas formed on engineered particles either
increased or mitigated the secretion of a specific cytokine, depending on the environment
where the protein corona was formed.178 According to the study, protein coronas could be
engineered as drug carriers for elongated circulation, enhanced biocompatibility, and
lower toxicity by triggering a specific immune response.178
Among the various cationic polymers used for therapeutics, polyethylenimine
(PEI) and modified PEIs are still some of the most widely studied systems especially for
the delivery of DNA, RNA and siRNAs.179-180 PEIs therefore serve as a benchmark for
polymeric therapeutics and can serve as an excellent model for investigating delivery
mechanisms. For example, in vitro processes of PEI-based polyplexes have been
systematically studied to understand cellular internalization, intracellular trafficking, and
release.58, 181 However, the overall goal in nonviral gene delivery is to develop nonviral
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transfecting agents suitable for in vivo applications where PEI polyplex nanoparticles
encounter and interact with proteins and other biological macromolecules. Polyplexes in
vivo, like other nanoparticles, also encounter nonspecific protein binding often forming
large aggregates as well as coronas.182-183 The formation of a protein corona formed with
PEI/DNA polyplexes reduces its interaction with cell membrane by several orders of
magnitude.183 It has been proposed that nonspecific protein interactions dissociate the
polyplex prematurely resulting in the unpackaging of the particle cargo and negatively
impacting the cellular internalization process. In contrast, there are also reports of protein
coronas positively impacting nanoparticle efficacy. For example, mechanistic studies
show that pre-formed corona on PEI/DNA polyplex with bovine serum albumin activates
the caveolae-mediated endocytosis pathway resulting in enhanced gene transfection or
silencing.184-185
In chapter 2, we have discussed the gene transfection efficacy with minimally
succinylated PEI even at only 2% modification. Luciferase expression with zPEI 2 was
found to be 260- to 480-fold higher than unmodified PEI in HEK 293 and HeLa cells,
respectively, when transfected in the presence of serum proteins.124 Especially for zPEI 2,
we saw no significant change in the protein-DNA interactions nor cytotoxicity, yet still
obtained a large enhancement in transgene expression compared to unmodified bPEI. We
hypothesized that one possibility for this enhancement could be that zPEI modifies the
ability of the polyplex to form coronas either by forming coronas faster or altering the
protein make-up within the corona. Recently, another study showed that bPEI polyplexes
precoated with BSA resulted in enhanced transfection.109 Using other nanoparticles, prior
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studies showed that a strategic choice of materials can greatly influence the types of
protein adsorbed on nanoparticles and improve gene delivery efficiency.186 187
Delivery of polyplexes in vivo results in nanoparticles being exposed to high
concentrations of serum proteins in the blood. In this work, we investigated the effect of
varying bovine serum albumin (BSA) concentrations in gene transfection with
succinylated PEI (zPEI)/DNA polyplexes and compared the efficacy with unmodified
PEI. Albumin is a major component (50-60%) of the blood plasma proteins and therefore
a good model for intravenous delivery of polyplexes. Transgene expression was
investigated for zPEI/DNA at a variety of polymer:DNA weight ratios. Finally, to test if
these conditions may lead to the formation of a protein corona on the nanoparticles, we
also measured the transgene expression of polyplexes pre-treated to form a protein corona
on un-treated polyplexes.
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4.2

4.2.1

Materials and Methods

Materials
Succinylated PEIs (2-11.5%) were used for all transfection experiments from the

previously synthesized series described in detail in chapter 2.124 HEK293 cell line was
purchased from the American Type Culture Collection and cryopreserved in-house for
further need. Cell lines were cultured at 37 °C, 5% CO2, and in the presence of 10% fetal
bovine serum (FBS) per ATCC recommendations. The pGL3 luciferase expression vector
was purchased from Elim BioPharm (Hayward, CA).

4.2.2

Polyplex transfection
HEK 293 cell line was cultured in EMEM supplemented with 10% FBS according

to ATCC recommendations. Cell lines were seeded in 24-well plates at 7.5 x 104
cells/well 24 h before transfection. Polymer/DNA complexes were formed by diluting 20
μL of 0.1 μg/μL DNA solution with 80 μL of PBS (1X) in a 1.5 mL microcentrifuge tube.
Polymer solutions (100 μL) at various concentrations were added dropwise to the DNA
solution under constant agitation to achieve the desired polymer: DNA weight ratio.
Particles were allowed to incubate at room temperature for 20 min. Immediately before
transfection, 200 μL polyplex solution was deposited into 1.8 mL of transfection medium
depending on the particular need of the experiment. For the first part of the project,
varying bovine serum albumin (BSA) concentration (0, 1, 3, 6, and 10 mg/mL) was used
as a transfection medium. The regular growth medium was aspirated from cells and
replaced with 500 μL of polyplex/growth medium solution (0.5 μg DNA/well). After four
hours, the transfection medium was replaced with a serum-supplemented growth
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medium. Transfection efficiency was quantified via luciferase expression 24 h posttransfection. A Promega luciferase assay kit (Madison, WI) was used to measure protein
activity in relative light units (RLU) using a Synergy 2 plate reader (BioTek, Winooski,
VT). The results were normalized to total cell protein using a bicinchoninic acid (BCA)
assay from G-Biosciences (St. Louis, MO).
The second part of the project where pre-treated BSA was used for gene delivery
followed one of the two possible formulations. After 200 μL polymer-DNA mixing &
incubation, an equi-volume i) 1 mg/mL BSA or ii) 5% fetal bovine serum (FBS) was
further mixed with incubating for another 20 minutes to form a protein coat. Immediately
before transfection, 400 μL protein- treated polyplex solution was deposited into 1.6 mL
of transfection medium (serum-free, 10% FBS, or 100% FBS) depending on the
particular need of the experiment. After four hours, the transfection medium was replaced
with a serum-supplemented growth medium followed by luciferase expression quantified,
as discussed above.

4.2.3

Particle size measurement with DLS
Polymer/DNA complexes for DLS study were formed in 0.1x phosphate-buffered

saline (PBS) at the optimum transfection weight ratio for each modified and unmodified
polymer. After the 30 min incubation, the polyplexes were diluted to 1 μg of DNA/mL
using 0.1x PBS. The solution was then immediately read using a 90Plus/BI-MAS
automatic particle sizer (Brookhaven Instruments, Holtsville, NY). Each measurement
was taken in triplicate (n =3).
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4.2.4

Imaging of protein and polyplex interactions via fluorescently labeled BSA and
pDNA
Plasmid DNA was labeled with Cy5 (red) according to the protocol specified by

the manufacturer (Mirus Bio, Madison, WI). BSA conjugated with FITC (green) was
obtained from Invitrogen (Waltham, MA). HEK293 cells were seeded in 24-well glassbottom plates at 7.5 x 104 cells/well 24 h prior to transfection. Polymer/DNA complexes
were formed by diluting 20 μL of 0.1 μg/μL Cy5-labeled DNA solution with 80 μL of
PBS in a 1.5 mL microcentrifuge tube. The equi-volume polymer solution was added
dropwise to the DNA solution under constant agitation to achieve the desired
carrier/DNA weight ratio. Particles were allowed to incubate at room temperature for 30
min. Immediately before transfection, 200 μL polyplex solution was added to 1.8 mL of
EMEM containing 3 mg/mL of BSA, approximately the equivalent protein concentration
of 10% FBS. To prevent signal oversaturation, only 25% of the BSA solution was the
FITC conjugated form. Immediately after, the normal growth medium was aspirated from
cells and replaced with 0.5 mL of polyplex/BSA-FITC containing medium (0.5 μg
DNA/well). Transfection was allowed to proceed for 30 min in order to capture the early
trafficking stages of the particles. From here, the transfection media was aspirated, and
the cells were gently washed twice with PBS. The cell membrane was then stained using
BioTracker 400 Cytoplasmic Membrane Dye (blue) according to the suggested protocol
from the manufacturer (Sigma Aldrich, St. Louis, MO). After, the cells were washed
three more times to remove excess dye and then immediately imaged using a Cytation 7
multimode plate reader (BioTek, Winooski, VT).
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4.2.5

Statistical testing

Results were presented as average ± SD and the number of replicates (n ≥ 3). Statistical
significances were analyzed using one way ANOVA. All pairwise multiple comparison
procedures were conducted with Holm-Sidak method where an overall significance level
= 0.05. Significance levels were indicated with the following symbols: #, * p ≤ 0.05; ** p
≤ 0.01; and *** p ≤ 0.001.
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4.3

4.3.1

Results and Discussion

Gene transfection at varying BSA concentration
As mentioned before, the first part of the project was to investigate the effect of

varying protein concentrations in gene transfection mediated by minimally modified
zPEIs and compare the efficacy with unmodified PEI (Figure 4.1). Previously, we
transfected in 10% fetal bovine serum (FBS) solution (~3.5 mg/mL total protein), but
protein concentrations in blood are significantly higher (approximately 60-80 mg/mL)
with over half of the proteins present being albumin. FBS is the supernatant after blood
from a bovine fetus coagulates and therefore is a complex mixture of proteins that can
vary in content from batch to batch. For simplicity, we performed these experiments in
pure bovine serum albumin (BSA) solutions. Luciferase activity in the cell lysate is
reported as RLU normalized by the mass of total protein in the lysate. From prior results,
bPEI and zPEI 2 performed best for transgene expression at a polymer/DNA wt ratio of
1:1.159 Therefore, we examined the transgene expression of bPEI and zPEI 2 at this
weight ratio as a function of increasing BSA concentration (Figure 4.1 a/b). BSA at the
lowest concentration (1 mg/mL or ~5% FBS equivalent) moderately improves the
transfection efficiency of both uPEI and zPEIs. Two possible explanations for this could
be (1) that the presence of a small amount of serum protein leads to higher transfections
due to serum protein-cell interactions when compared to serum-free (BSA 0 mg/mL)
conditions or (2) because polyplexes are made with an excess of cation, and free PEI is
cytotoxic to cells, adding a small amount of BSA may preferentially complex this free
bPEI enhancing cell viability. However, when BSA concentration in the EMEM was
higher than 3 mg/mL, we see a drop in luciferase expression for bPEI (Figure 4.1a)
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while zPEI 2-mediated luciferase expression remains high up to 6 mg/mL but drops some
by 10 mg/mL BSA (Figure 4.1b). We next examined a series of minimally succinylated
PEIs (zPEIs 2-11.5%) for their resulting luciferase expression at different BSA
concentrations at the same polymer:DNA (wt:wt) loading ratio of 1. The results are
plotted in Figure 4.1c. Similar to results discussed in Chapter 2, the higher degree of
succinylation (>9%) transfected poorly. Similar to transfection in FBS, bPEI-DNA
luciferase expression decreases at BSA concentrations >1 mg/mL. zPEI 2 performs better
at higher BSA concentrations particularly at 3 and 6 mg/mL. The low protein expression
for higher zPEI modifications is presumably due to the poor complexation of these
polyplexes at wt:wt ratio 1.

Figure 4.1. Comparative gene transfection efficacy mediated by a) bPEI, b) zPEI 2 and
c) zPEI 0-11.5% in the presence of varying BSA concentrations (0, 1, 3, 6, 10 mg/mL).
The efficacy was measured as relative light unit RLU/ total mg of protein. Polyplex was
prepared at polymer/DNA weight ratio 1. All the experiments were triplicated (n=1).

We next compared the in vitro transfection efficiency of our bPEI, zPEI 2, and
zPEI 6.5 polyplexes in HEK293 cells at different polymer:DNA (wt:wt) loading ratios in
the presence of varying amounts of BSA protein (Figure 4.2). All experiments were done
in triplicates with error bars representing the standard deviation. Each polymer had
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mediated highest transgene expression at 1 mg/mL BSA concentration (Figure 4.2 a, b,
c) similar to results in Figure 4.1. The maximum gene expression for bPEI/DNA occurs
at 1 mg/mL but only for wt:wt 1 potentially supporting the idea that low concentrations
of BSA initially complex the uncomplexed PEI in solution. At higher wt:wt ratios, where
BSA is likely to interact with the polyplex after binding all the free bPEIs, the luciferase
drops significantly. For bPEI/DNA, at higher BSA concentrations, all weight ratios show
lower luciferase expression. In contrast, zPEI 2 and 6.5 mediate higher transgene
expression than bPEI at all weight ratios. zPEI 6.5 is lowest at wt:wt 1 but increases with
higher polymer loading and is relatively constant for all wt:wt ratios > 1. Because
succinylation adds a negative charge on PEI amines, more zPEI 6.5 polymers are
required to fully condense the DNA so wt:wt 1 is likely an incomplete condensation of
the DNA in the polyplexes. At higher wt:wt, a fully condensed zPEI 6.5 polyplex is
formed and all show enhanced transfection. zPEI 2, on the other hand, only modifies
approximately 12 of the 582 amines in a 25kDa PEI so does not significantly change the
polymer interactions with DNA compared to unmodified PEI. As shown in Chapter 2,
both form fully condensed polyplexes by wt:wt 1. Overall, the data shows zPEI 2 and 6.5
have better transfection efficacy over higher level of BSA concentrations when compared
to the unmodified bPEI. Figure 4.2d shows the statistical significance of the transgene
expression obtained with bPEI at varying low BSA concentrations (0-3 mg/mL) to further
explore the maximum observed at 1 mg/mL in Figure 4.2a. Although we see unmodified
PEI apparently aids in transgene expression in Figure 4.2d at 0.5 and 1 mg/mL BSA in
EMEM medium, these values are statistically not significant compared to the control (0
mg/mL protein) with an overall significance level 0.05. Differences in mean transgene
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Figure 4.2. Gene transfection ability at varying BSA concentration and polymer/DNA
weight ratio with a) bPEI, b) zPEI 2, and c) zPEI 6.5, respectively. The numbers in the
legends are the polymer/DNA weight ratio (representative color, from left to right).
Figure 2d shows the relationship between luciferase expression and BSA concentration
mediated by bPEI. All the experiments were triplicated (n≥3).
expression in bPEI/DNA are statistically significant when comparing transfections in 0.5
mg/mL BSA to transfections at 2 mg/mL (* p < 0.05), 3 mg/mL (** p < 0.01) and 10%
FBS (***p < 0.001). So, we conclude the low BSA concentration (<1 mg/mL) are
statistically similar in transfection efficacy compared to the control (0 mg/mL), and only
at higher BSA concentrations do we observe the proteins having a negative impact on
bPEI-mediated transgene expression. This data contradicts previously published findings
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that increasing protein concentration does not have a harmful effect on gene
transfection.184-185

4.3.2

Colocalization Studies by Fluorescence Microscopy
We used fluorescence microscopy to visualize the internalization of bPEI/DNA

and zPEI 2/DNA polyplexes into HEK293 cells. For these experiments, polyplexes
containing Cy5-labeled DNA (red emission) were complexed with polymer to a
polymer:DNA wt:wt ratio of 1. Immediately before transfection, polyplexes were added
to a 3 mg/mL BSA solution. This concentration of BSA was chosen as it corresponds to
the approximate BSA concentration in 10% FBS which was used previously in chapter 2
and chapter 3 for all transfections in serum. FITC-labelled BSA (green emission) was
added at a 1:3 weight ratio with unlabeled BSA to enable colocalization studies to be
performed. This ratio of labelled BSA was chosen to avoid oversaturation in our
microscopy images. Our goal in these experiments was to examine the early trafficking
stages in HEK293 by these two systems. The results are shown in Figure 4.3. In general,
we found that zPEI 2/DNA forms smaller homogeneous particles, as indicated by the
yellowish green particles near the cell membranes (Figure 4.3b). The yellow color is a
result of colocalization of the green-labeled BSA and red-labeled DNA most likely due to
BSA complexed with the zPEI 2/DNA polyplexes.188-189 This suggests the formation of a
partial or complete BSA protein coating. Unmodified bPEI/DNA, in contrast, was
observed to form large aggregates in the same 3 mg/mL BSA transfection medium
(Figure 4.3a). One possible explanation for this finding is that zPEI 2/DNA is more
readily forming a stable, protective BSA protein corona as compared to bPEI. Another
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possible explanation is that the uncomplexed bPEI and zPEI 2 in the polyplex solution
interact differently with BSA enhancing the interaction and uptake of zPEI polyplexes
into cells. More studies are required to differentiate between these cellular internalization
and trafficking mechanisms.

Figure 4.3. Imaging of protein and polyplex interactions via fluorescently labeled BSA
and pDNA. The figure shows the confocal fluorescence microscopy images of a) bPEI
and b) zPEI 2 captured 30 minutes after initial transfection on HEK 293 cell line. The
images are a composite of three different fluorescent channels associated with Cytation 7:
Cy5 (red), GFP (green), DAPI (blue). Standard transfection protocol was used with 10%
FBS as a medium. Scale bar = 300 μm.

4.3.3

Particle size of protein pre-treated polyplexes
DLS was used to measure the effective hydrodynamic diameter of the complexes

formed at the polymer/DNA weight ratio of 3, which resulted in full DNA condensation
for all zPEI formulations (0-11.5% modification). Results are given in Table 4.1.
Polyplexes were formed in phosphate buffered saline (0.1x PBS, pH 7.4) and equilibrated
for 30 mins. Nanoparticle diameters ranged from 70 to 186 nm for these polyplexes with
the smallest particles being unmodified PEI/DNA. With increasing degrees of
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succinylation, zPEI/DNA polyplex nanoparticles were observed to increase in size. In
another set of experiments, we formed polyplexes in the same manner in PBS and then
added an equal volume of 1 mg/mL BSA and incubated for 20 minutes. In all cases,
BSA complexed with the polyplexes to form larger aggregates (~400-860 nm in
diameter). Interestingly, the trend in the size of BSA-polyplex complexes is reversed that
was observed for the polyplexes alone. The largest complex sizes were observed for
bPEI-DNA with BSA. With increasing succinylation, the BSA-zPEI-DNA complexes
formed with smaller diameters. While the mechanism for this observation is still not
known, we hypothesize that the presence of the succinyl groups on the PEI alter the
interactions

Table 4.1. Particle size comparing bPEI and zPEI polyplexes formed in PBS buffer or in
the presence of 1 mg/mL BSA
Name of polymer
Particle diameter in
Particle diameter in

bPEI

PBS (nm)
70±2.1

1 mg/mL BSA* (nm)
857.1±14.2

zPEI 2

73.6±3.7

787.2±11.5

zPEI 6.5

105.5±0.8

491.2±8.6

zPEI 9

132.8±3.6

466.8±7.3

zPEI 11.5

186.4±2

403±6.4

*After polyplex formation, an equi-volume 1 mg/mL BSA was mixed and allowed to
incubate for 20 minutes before diluting to 1 ml with 0.1x PBS.
of the mixed charge zPEI polymers with BSA proteins which is net negatively charged
but also has both positive and negatively charged moieties. This may result in a faster
formation of neutral but stable BSA protein coating on the nanoparticle or could create
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BSA-zPEI ‘ghost particles’ that help mitigate the aggregation of the polyplexes more
than BSA-bPEI complexes.

4.3.4

Gene transfection with pre-treated polyplex
Recent studies have suggested that pre-coating bPEI/DNA polyplexes can result

in enhanced gene transfection.109, 190 As it is unclear currently if our transfections in BSA
(Figure 4.1/4.2) result in complete protein corona formation or not, we conducted
experiments to test the effect of pre-treating polyplexes of bPEI and zPEI 2 with BSA
protein. For these experiments, polyplexes were formed in the same manner as before but
then treated with 1 mg/mL BSA or 5% FBS serum and incubated for an additional 20
minutes. Zhu et al. showed that this concentration of protein and incubation time was
sufficient to form a corona around bPEI/DNA polyplexes.109,

190

Immediately before

transfection into HEK293 cells, these pre-treated polyplexes were mixed with the
transfection medium specific to the experiment and added to cells. When pre-treated with
1 mg/mL BSA, this results in a polymer/DNA/BSA weight ratio of 1/1/100 in the
incubated solution. In Figure 4.4, we show the results of experiments comparing pretreated polyplexes directly to non-treated polyplexes. Specifically, the luciferase
expression was measured for non-treated and BSA treated polyplexes in two different
transfection conditions with the medium being either serum free medium or a ‘in serum’
medium consisting of 10% FBS solution. It is well known that unmodified bPEI/DNA is
an excellent transfecting agent in serum-free conditions, but the efficacy goes down
significantly in the presence of serum proteins. This is exactly what we see in Figure
4.4a when comparing bPEI/DNA in serum free (black) vs in serum (red) where the

133

luciferase expression drops by more than 100-fold. Similar to the results of Zhu et al,109
we also see that pre-treating the bPEI/DNA polyplexes with 1 mg/mL BSA for 20 min
increases the luciferase expression modestly for serum-free conditions (orange) but
significantly for transfection in serum (purple). Similarly, pre-treating with 5% FBS
solution also results in better transfection in serum-free conditions (dark blue), but FBS
treated bPEI/DNA performed worse in serum (light blue). In contrast, the non-treated
zPEI 2/DNA polyplexes transfected higher than bPEI/DNA in serum-free conditions and
significantly higher for in serum similar to results discussed in chapter 2.

Figure 4.4. Gene transfection of pre-treated vs. non-treated particles with a) bPEI and b)
zPEI 2 at different transfection conditions. BSA pre-treating was done at 1 mg/mL BSA
in EMEM, while FBS pre-treating was done at 5% FBS in EMEM media. In serum
means where 10% FBS was used as transfection media (P<0.05), serum-free means no
serum present in the media. Polyplex formed at polymer/DNA weight ratio 1. All the data
was obtained in triplicates (n=3).
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Pre-treating the zPEI 2/DNA polyplexes with BSA resulted in similar high transgene
expression both in serum and serum free conditions. FBS pre-treated zPEI/DNA
polyplexes behaved similar to bPEI/DNA in both serum free and in serum conditions.
One point to note here is that zPEI 2 shows a lesser gene expression in serum than gene
expression in the absence of serum. While compared to the gene expression mediated by
bPEI in the absence of serum seems comparable to zPEI 2. The data presented herein,
Figure 4.4b, was obtained at polymer/DNA wt ratio one, where bPEI performs the best.
However, this data is similar to what we observed in chapter 2, where zPEI 2 shows
higher gene expression with a higher polymer/DNA loading wt ratio. The most important
finding from this experiment is that gene transfection efficiency of bPEI decreases more
than a hundred-fold while zPEI 2 maintains a significant transfectability both in the
presence or absence of serum.
Taken together, these results suggest that both bPEI and zPEI polyplexes when
pre-treated with BSA or FBS protein solutions give comparable transgene expression.
This may suggest that when a protein corona is fully formed, the transfection efficacy is
controlled more by the interaction of the cells with the corona proteins and is not as
sensitive to the small modification differences between bPEI and zPEI 2. The most
significant differences were found when comparing BSA treated and non-treated bPEI
and zPEI 2 in either serum-free or in serum conditions. For bPEI, pre-treating polyplexes
with BSA greatly enhances transfection in serum while zPEI 2 shows similar results in
both untreated and BSA treated samples. One possible explanation for these results is that
succinylated polyplexes may form a more complete protein coating faster when
compared to bPEI/DNA. More experiments are needed to better understand these results.
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One other thing to note is that the results in pre-coating with BSA and precoating with the
more complex mixture of proteins in 5% FBS still resulted in similar transfection results
in both bPEI and zPEI 2. This may be due to the FBS corona being predominantly
formed by BSA depositing on the polyplexes or may suggest that the identity of protein
composition do not have significant impact in gene expression. In future studies, it could
be interesting to examine transgene expression in preformed coronas consisting of
proteins not common to serum.

4.3.5

Gene transfection with pre- treated polyplex at higher serum conditions
In a final set of experiments, we next examined the effect of non- treated and pre-

treated polyplexes at varying polymer:DNA wt ratios (1-6) under three different
transfection conditions. In Figure 4.5a, we show bPEI, zPEI 2, and zPEI 6.5 polyplexes
transfected in 10% FBS medium. In Figure 4.5b, we looked at the same polyplexes
transfected in 10% FBS after pre-treating the polyplexes with 1 mg/mL BSA. In Figure
4.5c, we again pre-treated the polyplexes with 1 mg/mL BSA but then transfected in
100% FBS. In non-treated polyplexes, we see nearly identical results to the 10% FBS (or
"in serum") transfections discussed in chapter 2. At all polymer:DNA ratios, zPEI 2
shows significantly higher (~100-fold) transgene expression when compared to
bPEI/DNA. We do note, in these experiments we do see lower transfection for zPEI 2
than in chapter 2 however we do note that FBS is complex solution of proteins that is
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Figure 4.5. Comparative gene transfection efficacy in a) standard in serum (10% FBS in
EMEM) b) pre-treated with 1 mg/mL BSA and transfection in serum (10% FBS in
EMEM) & c) pre- treated with 1 mg/mL BSA and transfection in 100% serum with bPEI,
zPEI 2 and zPEI 6.5 respectively. All the data collected as a triplicate (n = 3 and P<0.05).
known to have significant differences in the serum constituents that vary from batch to
batch and therefore show different interaction behavior with polyplexes.124, 191-192 Except
the polymer/DNA wt ratio 2, zPEI 2 show no significant variability in gene expression
with increasing loading ratio (Figure 4.5a, *P<0.05). zPEI 6.5 shows similar enhanced
transfection over bPEI but only at polymer/DNA ratios (wt:wt) of 2 and above.
When we pre-treat the polyplexes with BSA (Figure 4.5b), the transgene
expression is nearly identical at all three polyplexes. Surprisingly even at high
polymer:DNA ratios, where there is more free polycation available to potentially
complex and bind with BSA and thus presumably less BSA available to be incorporated
into the pre-treated protein polyplex, the transgene expression seem stable up to wt:wt 6.
However, as we discussed at polymer:DNA ratio 1, having a concentration of 1 mg/mL
BSA is still sufficient to have nearly 100 BSAs available per polyplex. Therefore even at
wt:wt 6, there is still a large excess of BSA available to form the corona. We also cannot
exclude the possibility of ghost particles of BSA-PEI also being incorporated in the
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protein corona surrounding the PEI and zPEI polyplexes. For the first time, we also
performed transfections in 100% FBS medium or 10-fold higher protein concentration in
the transfection medium compared to our previous ‘in serum’ experiments. Transfection
in 100% FBS is not common, but as our ultimate goal is for in vivo gene transfection,
100% FBS should more closely resemble the protein concentrations experienced by
polyplexes in the body. Again, the pretreated polyplexes are quite similar for all three
systems except some variability observed in bPEI- and zPEI 6.5-mediated gene
expression due to polymer/DNA loading ratio (Figure 4.5c, *, #P<0.05). The one
exception is zPEI 6.5 at wt:wt 1 but as discussed these are not fully formed polyplexes
and at higher polymer concentrations we see zPEI 6.5 expression increase back to
comparable or higher levels than the pre-treated bPEI and zPEI 2 polyplexes. While these
results do not explain the mechanism of enhanced transfection for minimally succinylated
PEIs in the presence of serum, they are in good agreement with the recent results of Zhu
et al., suggesting pre-coating polyplexes, whether bPEI or zPEI, results in enhanced gene
transfection in serum even at 100% FBS concentrations.

4.4

Conclusion
These experiments investigated the effect of varying BSA concentrations (0, 1, 3,

6, 10 mg/mL) on gene transfection mediated by unmodified bPEI as well as minimally
modified zPEIs. We find that transgene expression decreases with increasing BSA
concentration for bPEI/DNA. zPEI 2 and zPEI 6.5 however show higher gene
transfection over a wider range of BSA concentrations (0-6 mg/mL). Lastly, a series of
experiments were performed to compare polyplexes pre-treated with BSA compared to
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the non-treated polyplexes transfected in the presence of protein solution medium. For
bPEI/DNA, the presence of pre-formed BSA corona showed clear enhancement of
transgene expression when compared to transfection by bPEI/DNA polyplexes that did
not have a pre-formed corona. In all three systems, the treatment with varying
concentrations of proteins to favor pre-formed corona, transfection efficacy was quite
similar, suggesting that transgene expression may be more dominated by the corona-cell
interactions and not significantly influenced by low levels of succinylation. zPEI/DNA,
in contrast, showed high transgene expression both with and without a pretreated protein.
More experiments are needed to investigate the complex correlation between zPEI-DNA
particles with protein coating to facilitate enhanced gene expression.
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CHAPTER 5. CONCLUSION AND FUTURE RESEARCH DIRECTION
With this work, a series of minimally succinylated PEI were synthesized and
evaluated for their transgene expression efficacy in vitro. In chapter 2, the transfection
efficacy of these succinylated PEI (zPEI 2-11.5) was compared with unmodified
branched PEI and commercial PEGylated PEI. The in-vitro efficacy mediated by zPEI 2
was reported 260- to 480-folds higher than that of unmodified PEI and more than 50folds higher than PEGylated PEI in the presence of serum in HEK293 and HeLa cells,
respectively. zPEI 2 was also able to repair a gene via CRISPR/Cas9 homology-directed
repair mechanism, which was more than 16-folds higher than bPEI and Lipofectamine
(2kDa) in the presence of serum. We concluded that this enhanced transgene expression
efficacy with minimally succinylated PEI was not correlated to serum protein interaction;
instead, a controlled interaction could benefit stable transgene expression.
In the future, a mechanistic study should be conducted to investigate how zPEI
interacts with the cell membrane. In the second chapter, we hypothesized succinylation
could potentially incorporate succinate receptor-mediated endocytosis. If this hypothesis
is true, it could open another cell- specific therapy customized for certain organs such as
the kidney. In situ physicochemical properties of the polyplexes should also be
investigated. One vital question to consider is can zPEI alter intracellular trafficking? or
how zPEI differs in cargo release compared to unmodified PEI? or does zPEI alters the
rate of nucleic acid release from its cargo? For these types of intracellular trafficking
experiments, a super-resolution imaging experiment should be incorporated. The
CRISPR/Cas9 homology-directed repair was conducted on HEK 293 cell line. In the
future, actual cancer cell line should be used to verify what level of correction we can
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achieve. A new set of gene should be developed to modify cancer cells. We haven’t
checked the mRNA delivery efficacy with minimally succinylated PEI yet, but
discussions are ongoing with a company so the DeRouchey and Pack labs may test
mRNA delivery in the near future. Work by summer REU students in 2021 also explored
the use of minimally succinylated PEI to transfect hard-to-transfect cell lines such as
macrophage cells. The initial results were very promising and more work along these
lines should be pursued in the future.
In chapter 3, we examined how the DNA packaging in PEI polyplexes changes
due to polymer modification and pH. For this purpose, a new series of succinylated and
acetylated PEI were synthesized and characterized with FT-IR and NMR spectroscopy.
2D-NMR (1H-13C HSQC, HMBC) experiments. Although modifications on PEI have
often been assumed to occur preferentially on primary amines due to steric hinderance,
using 2D-NMR we were able to show that both acetylation and succinylation actually
occur primarily on the secondary amines of bPEI. This is reasonable as secondary amines
are more nucleophilic than primary amines. In previous work, DeRouchey et al. showed
that incorporation of either an uncharged amino acid or a negatively charged amino acid
into short arginine peptides resulted in reduced attractions and increased repulsions
ultimately reducing the packaging density of the DNA in the condensate. Acetylated PEI
shows a similar trend with more loosely packaged DNA with increasing degrees of
modification but zPEI shows a crossover behavior with DNA-DNA spacings first
increasing and then decreasing at higher succinylation levels. Lastly, we showed that at
low pH comparable to a lysosomal environment, polyplexes with PEI and modified PEIs
all showed tighter DNA packaging.
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Some complimentary future experiments to this work could include polyplex
visualization by transmission electron microscopy to see if the polyplexes of the assorted
succinylated and acetylated PEIs form similar or different complexes when compared to
bPEI/DNA. These modifications could result in polyplexes that have more open
structures or form more fibrous elongated nanoparticles when compared to bPEI/DNA
which is known to form tightly compacted spherical or toroidal nanoparticles. zPEI/DNA
was observed to loosen structure at low modification but tighten the DNA packaging at
high modification, yet competition experiments show the highly modified zPEI
complexes were more unstable. In contrast the condensation of DNA by PEI at low pH
resulted in significantly tighter DNA packaging and presumably more stable polyplexes.
This was not tested however so an interesting follow-up experiment would be to look at
DNA condensation and release with polyplexes formed at low pH. Molecular dynamic
simulations also suggested acidification of PEI/DNA may lead to more polycation being
released from the complex and this could be experimentally validated. Lastly, since the
formation of coronas on polyplexes have been observed, other groups have suggested that
the proteins of the corona may interact and alter the DNA packaging of the polyplex
nanoparticles. This could also be experimentally determined using X-ray diffraction
experiments to determine DNA packaging in PEI and modified PEI polyplexes in the
presence of serum proteins or lysosomal enzymes. In the future, it is critical to know how
both pH and enzymes interplay in changing intra-helical spacings and the lysosomal
release. X-ray experiments should also incorporate live-cell imaging to support whether
polyplexes can evade lysosomal degradation due to polymer chemistry. Such experiments
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may shed light on the mechanism of why zPEI acts as a better gene transfecting agent in
the presence of serum proteins.
In chapter 4, gene transfection was conducted with bPEI and minimally modified
zPEIs polyplexes at varying BSA concentrations (0, 1, 3, 6, 10 mg/mL) in the
transfecting medium. The results of this chapter are very preliminary but offers some
insight into how bPEI/DNA and zPEI/DNA transfect in these high protein concentrations.
Most clearly, we see significant differences in bPEI/DNA when they are pretreated with
BSA as compared to transfections performed with non-treated polyplexes in the presence
of serum proteins. In contrast, zPEI/DNA shows little difference perhaps suggesting the
succinylation is enabling the formation of a stable protein corona in a shorter time scale
compared to bPEI/DNA. When pre- treated, both bPEI and zPEI shows high stability in
transgene expression in both 10 and 100% FBS solution. This preliminary work used
confocal fluorescence microscopy to observe colocalization of BSA and DNA in cells.
In future work, super-resolution microscopy could be incorporated to observe
particle trafficking within the cell. Much more work could be done to explore how pretreating polyplexes enhances gene transfection as well as distinguishing if there are
differences depending on the polycation used in the original polyplex. For instance, bPEI
and zPEI 2 seemed quite similar due presumably to a similar BSA corona formed on both
polyplexes but would this still be true if one significantly altered the polycation-DNA
interactions by using more highly succinylated or acetylated polymers in the pre-treated
polyplexes. Such particles should much more readily disassemble inside the cells altering
the DNA release dynamics. In addition, using different proteins than BSA could be
explored to see how non-serum proteins alter the uptake of pre-treated polyplexes into
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cells. Particularly integrating ligands into the protein corona to enhance cell target should
be performed. Mechanistic studies to understand how the presence of corona alters the
polyplex cell entry could also be pursued.
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APPENDICES
APPENDIX 1. Synthesis of polymers (PEI/reactant mole ratio calculation)
To conjugate x% succinyl/acetl group to the bPEI polymer (25kDa), first, the total
moles of nitrogen atoms were determined in the polymer. For simplification, a calculation
follows:

For 2% succinylation:

*Half a gram of PEI (500 mg) requires

500𝑚𝑚𝑚𝑚×582 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑁𝑁 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
25000𝑔𝑔×1 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑃𝑃𝑃𝑃𝑃𝑃

= 11.64 mmols N atoms

*For 2% succinylation, total N atoms should be modified = 0.02 x 11.64 = 0.2328 mmol
succinic anhydride should be reacted.

So, the amount of succinic anhydride will be =>
0.023296296 ~0.0233 g = 23.3 mg

𝑤𝑤

100.07𝑔𝑔

= 0.2328 mmol x

10¯³

1 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚

=

APPENDIX 2. Polymer/DNA wt/wt ratio converting to nitrogen/phosphate (N/P) ratio
calculation
As an example, polymer/DNA wt ratio one is used. In this example, 200 ng pDNA and
200 ng bPEI (25kDa) polymer was used.

The calculation is as follows:

200 ng pDNA => 2 x 10-7 g DNA = 2 x 10-7 g x

𝑂𝑂𝑂𝑂𝑂𝑂 𝑚𝑚𝑚𝑚𝑚𝑚 𝐷𝐷𝐷𝐷𝐷𝐷
660 𝑔𝑔/𝑚𝑚𝑚𝑚𝑚𝑚

= 3.03 x 10-10 mol DNA

Each base pair contains two phosphate groups, so, mols of phosphate in this DNA = 3.03
x 10-10 mol DNA x 2 PO4- = 6.06 x 10-10 mol PO4-

200 ng bPEI =

42

200 x 10¯⁹ g PEI

g
per N atom based on aziridine group
mol

So, the N/P ratio =

4.7619 x 10¯9 N

6.06 x 10−10 P

= 4.7619 x 10-9 mol N atom

= 7.86 ~ 8.

APPENDIX 3. NMR characterization parameters sample (H-NMR/HSQC/HMBC)
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